Anti-CD79 chimeric antigen receptor, CAR-T cells and their applications

By designing a chimeric antigen receptor (CAR) targeting CD79b to enhance the specific recognition and killing ability of immune cells, the shortcomings of existing CAR-T cell therapies in the case of CD19 antigen loss are addressed, and the treatment effect of CD79b positive tumors is improved.

CN114945590BActive Publication Date: 2026-11-10JANSSEN BIOTECH INC
View PDF 35 Cites 0 Cited by

Patent Information

Application Number
CN202080093567.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-11-18
Filing Date
2020-11-17
Publication Date
2026-11-10
Estimated Expiration
2040-11-17

AI Technical Summary

Technical Problem

Existing CAR-T cell therapies have low long-term remission rates in treating relapsed/refractory non-Hodgkin's lymphoma and diffuse large B-cell lymphoma caused by CD19 antigen loss, necessitating the development of novel immunotherapies targeting CD79b.

Method used

A chimeric antigen receptor (CAR) comprising an extracellular domain, a transmembrane domain, and an intracellular signal transduction domain targeting CD79b was designed for use in engineered immune cells to enhance specific recognition and response to CD79b.

Benefits of technology

It improves the ability to recognize and kill CD79b-positive tumors, enhancing treatment efficacy, especially for patients with CD19 antigen loss, providing a higher long-term remission rate.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114945590B_ABST
    Figure CN114945590B_ABST
Patent Text Reader

Abstract

This disclosure provides a chimeric antigen receptor (CAR) that specifically targets the differentiation cluster 79b protein (CD79b) and immune response cells containing such CARs for the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] sequence list

[0002] This application contains a sequence list that has been electronically filed in ASCII format, the entire contents of which are incorporated herein by reference. The ASCII copy was created on November 9, 2020, named JBI6171WOPCT1_SL.txt, and is 488,479 bytes in size. Technical Field

[0003] This invention relates to a chimeric antigen receptor (CAR) targeting CD79b comprising a single-stranded variable fragment targeting CD79b, and engineered immune cells expressing the CAR targeting CD79b. It also provides a nucleic acid encoding the CAR and an expression vector, recombinant cells comprising the vector, and compositions comprising engineered immune cells expressing the CAR targeting CD79b. Methods for preparing the CAR and engineered immune cells are also provided, as well as methods for treating diseases, including cancer, using engineered immune cells. Background Technology

[0004] T-cell therapy utilizes isolated T cells that have been genetically modified to enhance their specificity for specific tumor-associated antigens. Genetic modification can involve the expression of chimeric antigen receptors (CARs) or exogenous T-cell receptors to deliver novel antigen specificity to the T cells. T cells expressing chimeric antigen receptors (CAR-T cells) can induce tumor immune reactivity. Better cancer therapies utilizing CAR-T cells are needed.

[0005] Non-Hodgkin lymphoma (NHL) accounts for approximately 4% of all cancers. Despite improvements in available therapies, relapsed / refractory (r / r) NHL is characterized by a consistently poor prognosis. Adoptive immunotherapy using genetically engineered T cells expressing chimeric antigen receptors (CARs) has shown promising results for the treatment of CD19-positive B-cell malignancies, but even with initial overall response rates of approximately 60–80%, only 40% of patients achieve long-term complete remission [1,2]. Clinical data now emerging reporting disease relapse due to CD19 antigen loss in patients with acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) highlight the unmet clinical need for targeting novel surface antigens [2,4].

[0006] B cells (B lymphocytes) are a central component of adaptive immunity, responding to several different pathogens by producing antibodies, acting as antigen-presenting cells, secreting cytokines, and developing into memory B cells upon activation[5]. B cells circulate in the blood and lymphatic system. In lymphoid organs, they encounter their homologous antigens and, along with additional signals from T helper cells, can differentiate into effector plasma cells. These cells secrete specific antibodies that circulate in the blood to target and eliminate antigens or pathogens[6].

[0007] To detect antigens or pathogens, B cells possess B cell receptors (BCRs) on their cell surface. These receptors are multi-component receptors composed of transmembrane immunoglobulin molecules (mIg) and disulfide-linked heterodimers of CD79a (Igα) and CD79b (Igβ). CD79b is highly expressed in a wide variety of B-cell lymphomas. Its expression has been shown to be crucial for cancer cell viability in most DLBCL tumor models. Therefore, developing resistance to CD79b targets through antigen loss is unlikely, making it an attractive target for developing novel immunotherapies. Clinically, polotuzumab (Polivy) is used... TM ), an antibody-drug conjugate (ADC) molecule targeting CD79b, has recently been approved for the treatment of r / r DLBCL[7]. Polotuzumab treatment, when combined with standard care (bendamustine and rituximab), resulted in increased rates of complete response (CR) and duration of response (DOR), thus validating CD79b as a valuable clinical target[8].

[0008] Therefore, there is a need to develop CAR-T therapies that target CD79b. Summary of the Invention

[0009] This article discloses chimeric antigen receptors (CARs) (e.g., CARs targeting differentiation cluster 79B protein (CD79b)), CAR-containing cells, CAR-encoding vectors (e.g., recombinant expression vectors), and nucleic acid molecules encoding CARs, methods for preparing CARs, compositions, peptides, proteins, nucleic acids, host cells, cell populations, and methods for treating diseases (e.g., cancer) using the disclosed CARs.

[0010] In one aspect, a chimeric antigen receptor (CAR) is provided, the CAR comprising:

[0011] (a) An extracellular domain containing scFv that specifically binds to the differentiation cluster 79B protein (CD79b) antigen.

[0012] (b) Transmembrane domains, and

[0013] (c) Intracellular signal transduction domain, wherein the intracellular signal transduction domain optionally includes at least one co-stimulatory domain.

[0014] In some implementations, CAR also includes

[0015] (d) CD8a hinge area,

[0016] The transmembrane domain comprises a CD8a transmembrane region (CD8a-TM) polypeptide; and

[0017] The intracellular signal transduction domains include a co-stimulatory domain and a primary signal transduction domain. The co-stimulatory domain contains a component of TNF receptor superfamily member 9 (CD137), and the primary signal transduction domain contains a component of the T cell surface glycoprotein CD3ζ chain (CD3z).

[0018] In some embodiments, the CD8a hinge region contains an amino acid sequence that is at least 90% identical to SEQ ID NO:38;

[0019] The transmembrane domain contains an amino acid sequence that is at least 90% identical to SEQ ID NO:39; and / or

[0020] The intracellular signal transduction domain includes a co-stimulatory domain and a primary signal transduction domain. The co-stimulatory domain has an amino acid sequence that is at least 90% identical to that of SEQ ID NO:40, and the primary signal transduction domain has an amino acid sequence that is at least 90% identical to that of SEQ ID NO:41.

[0021] On the other hand, a chimeric antigen receptor (CAR) is provided, comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises:

[0022] The heavy chain complementarity-determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:208, the heavy chain CDR2 having the amino acid sequence of SEQ ID NO:209, and the heavy chain CDR3 having the amino acid sequence of SEQ ID NO:210.

[0023] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:216, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:217, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:218;

[0024] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:222, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:223, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:224;

[0025] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:228, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:217, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:229;

[0026] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:232, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:233, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:234;

[0027] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:238, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:239, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:240;

[0028] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:242, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:243, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:244;

[0029] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:248, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:249, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:250;

[0030] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:253, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:254, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:255;

[0031] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:257, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:258, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:259;

[0032] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:263, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:243, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:264;

[0033] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:268, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:269, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:270; or

[0034] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:274, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:275, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:276;

[0035] The extracellular antigen-binding domain binds to the CD79b antigen.

[0036] On the other hand, a chimeric antigen receptor (CAR) is provided, comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises:

[0037] Light chain CDR1 having the amino acid sequence of SEQ ID NO:211, light chain CDR2 having the amino acid sequence of SEQ ID NO:212, and light chain CDR3 having the amino acid sequence of SEQ ID NO:213;

[0038] Light chain CDR1 having the amino acid sequence of SEQ ID NO:214, light chain CDR2 having the amino acid sequence of SEQ ID NO:212, and light chain CDR3 having the amino acid sequence of SEQ ID NO:213;

[0039] Light chain CDR1 having the amino acid sequence of SEQ ID NO:215, light chain CDR2 having the amino acid sequence of SEQ ID NO:212, and light chain CDR3 having the amino acid sequence of SEQ ID NO:213;

[0040] Light chain CDR1 having the amino acid sequence of SEQ ID NO:219, light chain CDR2 having the amino acid sequence of SEQ ID NO:220, and light chain CDR3 having the amino acid sequence of SEQ ID NO:221;

[0041] Light chain CDR1 having the amino acid sequence of SEQ ID NO:225, light chain CDR2 having the amino acid sequence of SEQ ID NO:226, and light chain CDR3 having the amino acid sequence of SEQ ID NO:227;

[0042] Light chain CDR1 having the amino acid sequence of SEQ ID NO:230, light chain CDR2 having the amino acid sequence of SEQ ID NO:231, and light chain CDR3 having the amino acid sequence of SEQ ID NO:221;

[0043] Light chain CDR1 having the amino acid sequence of SEQ ID NO:235, light chain CDR2 having the amino acid sequence of SEQ ID NO:236, and light chain CDR3 having the amino acid sequence of SEQ ID NO:237;

[0044] Light chain CDR1 having the amino acid sequence of SEQ ID NO:241, light chain CDR2 having the amino acid sequence of SEQ ID NO:226, and light chain CDR3 having the amino acid sequence of SEQ ID NO:227;

[0045] Light chain CDR1 having the amino acid sequence of SEQ ID NO:245, light chain CDR2 having the amino acid sequence of SEQ ID NO:246, and light chain CDR3 having the amino acid sequence of SEQ ID NO:247;

[0046] Light chain CDR1 having the amino acid sequence of SEQ ID NO:251, light chain CDR2 having the amino acid sequence of SEQ ID NO:236, and light chain CDR3 having the amino acid sequence of SEQ ID NO:252;

[0047] Light chain CDR1 having the amino acid sequence of SEQ ID NO:251, light chain CDR2 having the amino acid sequence of SEQ ID NO:236, and light chain CDR3 having the amino acid sequence of SEQ ID NO:256;

[0048] Light chain CDR1 having the amino acid sequence of SEQ ID NO:260, light chain CDR2 having the amino acid sequence of SEQ ID NO:261, and light chain CDR3 having the amino acid sequence of SEQ ID NO:262;

[0049] Light chain CDR1 having the amino acid sequence of SEQ ID NO:265, light chain CDR2 having the amino acid sequence of SEQ ID NO:266, and light chain CDR3 having the amino acid sequence of SEQ ID NO:267;

[0050] Light chain CDR1 having the amino acid sequence of SEQ ID NO:271, light chain CDR2 having the amino acid sequence of SEQ ID NO:272, and light chain CDR3 having the amino acid sequence of SEQ ID NO:273; or

[0051] Light chain CDR1 having the amino acid sequence of SEQ ID NO:277, light chain CDR2 having the amino acid sequence of SEQ ID NO:266, and light chain CDR3 having the amino acid sequence of SEQ ID NO:278;

[0052] The extracellular antigen-binding domain binds to the CD79b antigen.

[0053] In some implementations, the extracellular antigen-binding domain further includes:

[0054] Light chain CDR1 having the amino acid sequence of SEQ ID NO:211, light chain CDR2 having the amino acid sequence of SEQ ID NO:212, and light chain CDR3 having the amino acid sequence of SEQ ID NO:213;

[0055] Light chain CDR1 having the amino acid sequence of SEQ ID NO:214, light chain CDR2 having the amino acid sequence of SEQ ID NO:212, and light chain CDR3 having the amino acid sequence of SEQ ID NO:213;

[0056] Light chain CDR1 having the amino acid sequence of SEQ ID NO:215, light chain CDR2 having the amino acid sequence of SEQ ID NO:212, and light chain CDR3 having the amino acid sequence of SEQ ID NO:213;

[0057] Light chain CDR1 having the amino acid sequence of SEQ ID NO:219, light chain CDR2 having the amino acid sequence of SEQ ID NO:220, and light chain CDR3 having the amino acid sequence of SEQ ID NO:221;

[0058] Light chain CDR1 having the amino acid sequence of SEQ ID NO:225, light chain CDR2 having the amino acid sequence of SEQ ID NO:226, and light chain CDR3 having the amino acid sequence of SEQ ID NO:227;

[0059] Light chain CDR1 having the amino acid sequence of SEQ ID NO:230, light chain CDR2 having the amino acid sequence of SEQ ID NO:231, and light chain CDR3 having the amino acid sequence of SEQ ID NO:221;

[0060] Light chain CDR1 having the amino acid sequence of SEQ ID NO:235, light chain CDR2 having the amino acid sequence of SEQ ID NO:236, and light chain CDR3 having the amino acid sequence of SEQ ID NO:237;

[0061] Light chain CDR1 having the amino acid sequence of SEQ ID NO:241, light chain CDR2 having the amino acid sequence of SEQ ID NO:226, and light chain CDR3 having the amino acid sequence of SEQ ID NO:227;

[0062] Light chain CDR1 having the amino acid sequence of SEQ ID NO:245, light chain CDR2 having the amino acid sequence of SEQ ID NO:246, and light chain CDR3 having the amino acid sequence of SEQ ID NO:247;

[0063] Light chain CDR1 having the amino acid sequence of SEQ ID NO:251, light chain CDR2 having the amino acid sequence of SEQ ID NO:236, and light chain CDR3 having the amino acid sequence of SEQ ID NO:252;

[0064] Light chain CDR1 having the amino acid sequence of SEQ ID NO:251, light chain CDR2 having the amino acid sequence of SEQ ID NO:236, and light chain CDR3 having the amino acid sequence of SEQ ID NO:256;

[0065] Light chain CDR1 having the amino acid sequence of SEQ ID NO:260, light chain CDR2 having the amino acid sequence of SEQ ID NO:261, and light chain CDR3 having the amino acid sequence of SEQ ID NO:262;

[0066] Light chain CDR1 having the amino acid sequence of SEQ ID NO:265, light chain CDR2 having the amino acid sequence of SEQ ID NO:266, and light chain CDR3 having the amino acid sequence of SEQ ID NO:267;

[0067] Light chain CDR1 having the amino acid sequence of SEQ ID NO:271, light chain CDR2 having the amino acid sequence of SEQ ID NO:272, and light chain CDR3 having the amino acid sequence of SEQ ID NO:273; or

[0068] Light chain CDR1 having the amino acid sequence of SEQ ID NO:277, light chain CDR2 having the amino acid sequence of SEQ ID NO:266, and light chain CDR3 having the amino acid sequence of SEQ ID NO:278. On the other hand, a chimeric antigen receptor (CAR) is provided, the CAR comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 208, 216, 222, 228, 232, 238, 242, 248, 253, 257, 263, 268, or 274; a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 209, 217, 223, 233, 239, 243, 249, 254, 258, 269, or 275; a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 210, 218, 224, 229, 234, 240, 244, 250, 255, 259, 264, 270, or 276; and a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 208, 216, 222, 228, 232, 238, 242, 248, 253, 257, 263, 268, or 274; and a heavy chain CDR4 having an amino acid sequence of SEQ ID NO: 209, 217, 223, 233, 239, 243, 249, 254, 258, 269, or 275; and a heavy chain CDR4 having an amino acid sequence of SEQ ID NO: 209, 217, 223, 233, 239, 243, 249, 254, Light chain CDR1 having an amino acid sequence of SEQ ID NO: 211, 214, 215, 219, 225, 230, 235, 241, 245, 251, 260, 265, 271 or 277; light chain CDR2 having an amino acid sequence of SEQ ID NO: 212, 220, 226, 231, 236, 246, 261, 266 or 272; and light chain CDR3 having an amino acid sequence of SEQ ID NO: 213, 221, 227, 237, 247, 252, 256, 262, 267, 273 or 278.

[0069] In some embodiments, the extracellular antigen-binding domain comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2, and the light chain CDR3 having the following amino acid sequence:

[0070] a) These are SEQ ID NO: 208, 209, 210, 211, 212, and 213, respectively;

[0071] b) are SEQ ID NO: 208, 209, 210, 214, 212 and 213 respectively;

[0072] c) are SEQ ID NO: 208, 209, 210, 215, 212 and 213 respectively;

[0073] d) are SEQ ID NO: 216, 217, 218, 219, 220 and 221 respectively;

[0074] e) are SEQ ID NO: 222, 223, 224, 225, 226 and 227 respectively;

[0075] f) are SEQ ID NO: 228, 217, 229, 230, 231 and 221 respectively;

[0076] g) are SEQ ID NO: 232, 233, 234, 235, 236 and 237 respectively;

[0077] h) are SEQ ID NO: 238, 239, 240, 241, 226 and 227 respectively;

[0078] i) are SEQ ID NO:242,243,244,245,246 and 247 respectively;

[0079] j) are SEQ ID NO: 248, 249, 250, 251, 236 and 252 respectively;

[0080] k) are SEQ ID NO: 253, 254, 255, 251, 236 and 256 respectively;

[0081] l) are SEQ ID NO:257,258,259,260,261 and262 respectively;

[0082] m) are SEQ ID NO:263,243,264,265,266 and 267 respectively;

[0083] n) are SEQ ID NO: 268, 269, 270, 271, 272 and 273 respectively; or

[0084] o) are SEQ ID NO:274,275,276,277,266 and 278 respectively.

[0085] In some implementations, the extracellular antigen-binding domain includes:

[0086] The region comprises a heavy chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:1 and a light chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:19;

[0087] The region comprises a heavy chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:1 and a light chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:20;

[0088] The region comprises a heavy chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:2 and a light chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:19;

[0089] The region comprises a heavy chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:2 and a light chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:20;

[0090] The region comprises a heavy chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:3 and a light chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:20;

[0091] The region comprises a heavy chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:4 and a light chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:19;

[0092] The region comprises a heavy chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:5 and a light chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:22;

[0093] The heavy chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:5 and a light chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:23;

[0094] The region comprises a heavy chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:6 and a light chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:24;

[0095] The region comprises a heavy chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:7 and a light chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:26;

[0096] The region comprises a heavy chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:8 and a light chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:25;

[0097] The region comprises a heavy chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:9 and a light chain variable region having at least 90% identity with an amino acid sequence that is identical to that of SEQ ID NO:27;

[0098] The heavy chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:10 and a light chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:28;

[0099] The heavy chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:11 and a light chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:29;

[0100] The heavy chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:12 and a light chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:30;

[0101] The heavy chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:13 and a light chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:31;

[0102] The heavy chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:14 and a light chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:32;

[0103] The heavy chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:15 and a light chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:33;

[0104] The heavy chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:16 and a light chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:34;

[0105] The heavy chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:16 and a light chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:35;

[0106] The heavy chain variable region comprises an amino acid sequence having at least 90% identity with SEQ ID NO:17 and a light chain variable region comprises an amino acid sequence having at least 90% identity with SEQ ID NO:33; or

[0107] The heavy chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:18, and the light chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:36.

[0108] In some implementations, the extracellular antigen-binding domain includes:

[0109] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:1 and the light chain variable region containing the amino acid sequence of SEQ ID NO:19;

[0110] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:1 and the light chain variable region containing the amino acid sequence of SEQ ID NO:20;

[0111] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:2 and the light chain variable region containing the amino acid of SEQ ID NO:19;

[0112] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:2 and the light chain variable region containing the amino acid sequence of SEQ ID NO:20;

[0113] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:3 and the light chain variable region containing the amino acid sequence of SEQ ID NO:20;

[0114] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:4 and the light chain variable region containing the amino acid sequence of SEQ ID NO:19;

[0115] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:5 and the light chain variable region containing the amino acid sequence of SEQ ID NO:22;

[0116] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:5 and the light chain variable region containing the amino acid sequence of SEQ ID NO:23;

[0117] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:6 and the light chain variable region containing the amino acid sequence of SEQ ID NO:24;

[0118] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:7 and the light chain variable region containing the amino acid sequence of SEQ ID NO:26;

[0119] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:8 and the light chain variable region containing the amino acid sequence of SEQ ID NO:25;

[0120] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:9 and the light chain variable region containing the amino acid sequence of SEQ ID NO:27;

[0121] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:10 and the light chain variable region containing the amino acid sequence of SEQ ID NO:28;

[0122] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:11 and the light chain variable region containing the amino acid sequence of SEQ ID NO:29;

[0123] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:12 and the light chain variable region containing the amino acid sequence of SEQ ID NO:30;

[0124] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:13 and the light chain variable region containing the amino acid sequence of SEQ ID NO:31;

[0125] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:14 and the light chain variable region containing the amino acid sequence of SEQ ID NO:32;

[0126] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:15 and the light chain variable region containing the amino acid sequence of SEQ ID NO:33;

[0127] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:16 and the light chain variable region containing the amino acid sequence of SEQ ID NO:34;

[0128] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:16 and the light chain variable region containing the amino acid sequence of SEQ ID NO:35;

[0129] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:17 and the light chain variable region containing the amino acid sequence of SEQ ID NO:33; or

[0130] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:18 and the light chain variable region containing the amino acid sequence of SEQ ID NO:36.

[0131] In some implementations, the extracellular antigen-binding domain includes:

[0132] The heavy chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:14, and the light chain variable region contains an amino acid sequence that is at least 90% identical to that of SEQ ID NO:32.

[0133] In some implementations, the extracellular antigen-binding domain includes:

[0134] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:14 and the light chain variable region containing the amino acid sequence of SEQ ID NO:32.

[0135] In some embodiments, the extracellular antigen-binding domain comprises a single-chain variable fragment (scFv). In some embodiments, the scFv comprises a linker polypeptide located between a light chain variable region (VL) and a heavy chain variable region (VH). In some embodiments, the linker polypeptide comprises an amino acid sequence having at least 90% identity with SEQ ID NO:42. In some embodiments, the linker polypeptide comprises the amino acid sequence of SEQ ID NO:42. In some embodiments, the scFv comprises an amino acid sequence having at least 90% identity with a sequence selected from the group consisting of SEQ ID NO:75-118. In some embodiments, the scFv comprises an amino acid sequence selected from the group consisting of SEQ ID NO:75-118. In some embodiments, the extracellular antigen-binding domain comprises a signal polypeptide. In some embodiments, the signal polypeptide comprises an amino acid sequence having at least 90% identity with SEQ ID NO:37. In some embodiments, the signal polypeptide comprises the amino acid sequence of SEQ ID NO:37.

[0136] In some embodiments, the intracellular signal transduction domain comprises a polypeptide component selected from: a TNF receptor superfamily member 9 (CD137) component, a T cell surface glycoprotein CD3ζ chain (CD3z) component, a differentiation cluster (CD27) component, a differentiation cluster superfamily member component, and combinations thereof. In some embodiments, the CD137 component comprises an amino acid sequence having at least 90% identity with SEQ ID NO:40. In some embodiments, the CD137 component comprises the amino acid sequence of SEQ ID NO:40. In some embodiments, the CD3z component comprises an amino acid sequence having at least 90% identity with SEQ ID NO:41. In some embodiments, the CD3z component comprises the amino acid sequence of SEQ ID NO:41. In some embodiments, the intracellular signal transduction domain comprises an amino acid sequence having at least 90% identity with SEQ ID NO:163. In some embodiments, the intracellular signal transduction domain comprises the amino acid sequence of SEQ ID NO:163. In some embodiments, the transmembrane domain comprises a CD8a transmembrane region (CD8a-TM) polypeptide. In some embodiments, the CD8a-TM polypeptide comprises an amino acid sequence having at least 90% identity with SEQ ID NO:39. In some embodiments, the CD8a-TM polypeptide comprises the amino acid sequence of SEQ ID NO:39.

[0137] In various embodiments, the CAR further includes a hinge region linking the transmembrane domain to the extracellular antigen-binding domain. In some embodiments, the hinge region is a CD8a hinge region. In some embodiments, the CD8a hinge region contains an amino acid sequence having at least 90% identity with SEQ ID NO:38. In some embodiments, the CD8a hinge region contains the amino acid sequence of SEQ ID NO:38.

[0138] In some embodiments, the extracellular antigen-binding domain comprises an amino acid sequence having at least 90% identity with a sequence selected from the group consisting of SEQ ID NO:119-162.

[0139] In some embodiments, the CAR has an amino acid sequence that is at least 90% identical to the sequence selected from the group consisting of SEQ ID NO:164-207. In some embodiments, the CAR comprises an amino acid sequence selected from the group consisting of SEQ ID NO:164-207.

[0140] On the other hand, a chimeric antigen receptor (CAR) is provided, comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises:

[0141] The heavy chain complementarity-determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:257, the heavy chain CDR2 having the amino acid sequence of SEQ ID NO:258, and the heavy chain CDR3 having the amino acid sequence of SEQ ID NO:259.

[0142] On the other hand, a chimeric antigen receptor (CAR) is provided, comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises:

[0143] Light chain CDR1 having the amino acid sequence of SEQ ID NO:260, light chain CDR2 having the amino acid sequence of SEQ ID NO:261, and light chain CDR3 having the amino acid sequence of SEQ ID NO:262.

[0144] In some embodiments, the extracellular antigen-binding domain may comprise the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2, and the light chain CDR3 having the following amino acid sequences: SEQ ID NO: 257, 258, 259, 260, 261, and 262, respectively.

[0145] On the other hand, a chimeric antigen receptor (CAR) is provided, comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises:

[0146] The CD79b antigen is defined as having a heavy chain variable region (VH) having an amino acid sequence that is at least 90% identical to that of SEQ ID NO:14 and a light chain variable region (VL) having an amino acid sequence that is at least 90% identical to that of SEQ ID NO:32, wherein the extracellular antigen-binding domain binds to the CD79b antigen.

[0147] On the other hand, a chimeric antigen receptor (CAR) is provided, comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises:

[0148] The heavy chain variable region (VH) having the amino acid sequence of SEQ ID NO:14 and the light chain variable region (VL) having the amino acid sequence of SEQ ID NO:32, wherein the extracellular antigen-binding domain binds the CD79b antigen.

[0149] In various embodiments, the extracellular antigen-binding domain comprises a single-chain variable fragment (scFv) containing a heavy chain variable region (VH) and a light chain variable region (VL). The scFv may also contain a linker polypeptide located between the heavy chain variable region (VH) and the light chain variable region (VL). In some embodiments, the linker polypeptide may contain an amino acid sequence having at least 90% identity with SEQ ID NO:42. In some embodiments, the linker polypeptide may contain the amino acid sequence of SEQ ID NO:42.

[0150] In some embodiments, the scFv may contain an amino acid sequence having at least 90% identity with SEQ ID NO:113. In some embodiments, the scFv may contain the amino acid sequence of SEQ ID NO:113.

[0151] In some embodiments, the extracellular antigen-binding domain may comprise a signaling polypeptide. In such embodiments, the signaling polypeptide may comprise an amino acid sequence having at least 90% identity with SEQ ID NO:37. In such embodiments, the signaling polypeptide may comprise the amino acid sequence of SEQ ID NO:37.

[0152] In some embodiments, the intracellular signal transduction domain may comprise a polypeptide component selected from the group consisting of: TNF receptor superfamily member 9 (CD137) component, T cell surface glycoprotein CD3ζ chain (CD3z) component, differentiation cluster (CD27) component, differentiation cluster superfamily member component, and combinations thereof. As a non-limiting example, the CD137 component may comprise an amino acid sequence having at least 90% identity with SEQ ID NO:40; the CD3z component may comprise an amino acid sequence having at least 90% identity with SEQ ID NO:41; and the intracellular signal transduction domain may comprise an amino acid sequence having at least 90% identity with SEQ ID NO:163. As another non-limiting example, the CD137 component may comprise the amino acid sequence of SEQ ID NO:40; the CD3z component may comprise the amino acid sequence of SEQ ID NO:41; and the intracellular signal transduction domain may comprise the amino acid sequence of SEQ ID NO:163.

[0153] In some embodiments, the intracellular signal transduction domain may comprise an amino acid sequence having at least 90% identity with SEQ ID NO:163. In some embodiments, the intracellular signal transduction domain may comprise the amino acid sequence of SEQ ID NO:163.

[0154] In some embodiments, the transmembrane domain may comprise a CD8a transmembrane region (CD8a-TM) polypeptide. In such embodiments, the CD8a-TM polypeptide may comprise an amino acid sequence having at least 90% identity with SEQ ID NO:39. In such embodiments, the CD8a-TM polypeptide may comprise the amino acid sequence of SEQ ID NO:39.

[0155] In some embodiments, the CAR disclosed herein may further include a hinge region linking the transmembrane domain to the extracellular antigen-binding domain. In some embodiments, this hinge region is a CD8a hinge region. In such embodiments, the CD8a hinge region may contain an amino acid sequence having at least 90% identity with SEQ ID NO:38. In such embodiments, the CD8a hinge region may contain the amino acid sequence of SEQ ID NO:38.

[0156] In some embodiments, the extracellular antigen-binding domain comprises an amino acid sequence having at least 90% identity with SEQ ID NO:157. In some embodiments, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:157.

[0157] In some embodiments, the CAR disclosed herein may comprise an amino acid sequence having at least 90% identity with SEQ ID NO:202. In some embodiments, the CAR disclosed herein may comprise the amino acid sequence of SEQ ID NO:202. In another embodiment, an isolated lymphocyte expressing any of the above-described CARs is provided. In some embodiments, the lymphocyte is a T lymphocyte. In some embodiments, the lymphocyte is a natural killer (NK) cell.

[0158] Also provided are isolated nucleic acid molecules encoding any of the aforementioned CARs. A vector containing the nucleic acid molecules is also provided. Furthermore, cells expressing the nucleic acid molecules are also provided.

[0159] Also provided is a pharmaceutical composition comprising an effective amount of any one of the above lymphocytes and a pharmaceutically acceptable excipient.

[0160] On the other hand, a method for treating a subject suffering from cancer is provided. The method includes administering a therapeutically effective amount of the above lymphocytes or any of the above pharmaceutical compositions to the subject in need, thereby inducing the lymphocytes to kill cancer cells in the subject. In some embodiments, the cancer is B-cell lymphoma. In some embodiments, the cancer is non-Hodgkin lymphoma. In some embodiments, the cancer is diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZ), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), mucosa-associated lymphoid tissue (MALT) lymphoma, Hodgkin lymphoma, Burkitt lymphoma, hairy cell leukemia, or plasmacytoma.

[0161] On the other hand, a method for targeted killing of cancer cells is provided, the method comprising contacting the cancer cells with any of the lymphocytes mentioned above, thereby inducing the lymphocytes to kill the cancer cells. In some embodiments, the cancer cells are malignant B cells. In some embodiments, the cancer cells are non-Hodgkin lymphoma cells. In some embodiments, the cancer cells are cells of diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZ), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), mucosa-associated lymphoid tissue (MALT) lymphoma, Hodgkin lymphoma, Burkitt lymphoma, hairy cell leukemia, or plasmacytoma.

[0162] On the other hand, a method for detecting the presence of cancer in a subject is provided, the method comprising:

[0163] (a) Contacting a cell sample obtained from the subject with any of the above-mentioned CARs to form a CAR-cell complex, and

[0164] (b) Detecting the complex, wherein the detection of the complex indicates the presence of cancer in the subject. Attached Figure Description

[0165] The foregoing will become apparent from the following more specific description of the exemplary embodiments shown in the accompanying drawings.

[0166] This patent application contains at least one color drawing. Upon request and payment of the necessary fees, the U.S. Patent and Trademark Office will provide a color copy of this patent application.

[0167] Figure 1This is a diagram illustrating the exemplary aCD79b CAR molecular structure. aCD79b scFv was cloned sequentially with the CD8a hinge / transmembrane domain, the CD137 intracellular domain, and the CD3ζ intracellular domain.

[0168] Figures 2A-2I This demonstrates the generation of primary human CAR-T cells expressing aCD79b CAR. Primary human T cells were isolated via negative selection and cultured in TexMACS medium using TransAct (Miltenyi) (…). Figures 2A-2C , Figure 2G-Figure 2I ), or use anti-CD3 / anti-CD28 beads (Dynabeads, Invitrogen) in Optimizer medium ( Figures 2D-2F Stimulation was performed. In both cases, the culture medium was supplemented with 100 U / mL IL-2 (Miltenyi). Cells were transduced with a lentiviral vector encoding the CAR construct 24 hours after stimulation and cultured for 12–14 days. The culture medium and cytokines were refreshed every 2–4 days. CD79b CAR expression was quantified by flow cytometry using the extracellular domain of recombinant human CD79b fused to the AF647 protein. The frequency of CAR+ cells is shown. Figure 2A -Figure AC and Figure 2E In this context, all SN8(CD9w) constructs are LH oriented.

[0169] Figures 3A-3F The aCD79b CAR demonstrated cytotoxicity against CD79b+ tumor cell lines. The aCD79b CAR was co-cultured with the indicated target cell lines at an indicated effector:target (E:T) ratio (based on CAR+ frequency) for 16–20 hours. Cells were then analyzed by flow cytometry after live / dead staining. Figure 3A ) or use the Promega BrightGlo kit, following the manufacturer's instructions, via the loss of luciferase signaling in tumor cells ( Figures 3B-3F Tumor lysis was evaluated using [a specific method / method]. In each case, the lysis percentage was calculated relative to the individual tumor condition. CAR dose-dependent antitumor activity was observed in CD79b+ target cells, with [a specific method / method] targeting CD79b [a specific tumor condition]. neg The target did not dissolve above the background. Figures 3A-3D In this model, all SN8 (CD9w) constructs are LH oriented. Figures 3E-3F In this context, HL orientation or LH orientation is indicated by the first letter.

[0170] Figures 4A-4DThe aCD79b CAR was shown to secrete cytokines in response to stimulation by antigen-positive tumor cells. Supernatant from the co-culture setup shown in Figure 3 was harvested 16–20 hours after setup, and cytokines were quantified using an MSD kit (MesoScale Diagnostics) according to the manufacturer's protocol. The aCD79b CAR exhibited antigen-dependent cytokine production. Figures 4A-4C In this model, all SN8 (CD9w) constructs are LH oriented. Figure 4D In this context, HL orientation or LH orientation is indicated by the first letter.

[0171] Figures 5A-5C This demonstrates the specific proliferation of aCD79b CAR in the presence of the antigen. aCD79b CAR was labeled with CellTraceViolet (CTV) according to the manufacturer's instructions (Invitrogen). Labeled CAR-T cells were co-cultured with the indicated target at a 1:2 E:T ratio for 4–5 days, followed by staining with CAR detection reagent (recombinant CD79b-AF647). CAR+ cell proliferation was then analyzed by flow cytometry. The CTV dilution of CAR+ cells is plotted. aCD79b CAR specifically showed CTV dilution (proliferation) after stimulation with CD79b+ tumor lines, while non-antigen-negative target lines showed CTV dilution. Figures 5A-5C In this model, all SN8 (CD9w) constructs are LH oriented. Figure 5C In this context, HL orientation or LH orientation is indicated by the first letter.

[0172] Figure 6 The aCD79b CAR demonstrated long-term cytotoxicity against CD79b+ tumor cell lines. The aCD79b CAR was co-cultured with the indicated RFP-expressing target cell lines for 4–7 days at an indicated effector:target (E:T) ratio (based on CAR+ frequency). Cells were imaged every 4 hours after proliferation and used... The technique calculates total RFP + area / well. Growth inhibition is calculated for each construct in the tested construct. Figure 6 In this context, all SN8(CD9w) constructs are LH oriented.

[0173] Figures 7A-7C Demonstrates aCD79b CAR-T cell eradication of CD79b+ tumors in vivo. (NOD / scid / IL-2Rg) - / - (NSG) mice subcutaneously implanted 5x10 5 1 CARNAVAL cell. When the average tumor volume of the group reached approximately 50 mm. 3 -100mm 3 / mice, intravenous injection of CAR-T cells ( Figure 7A Tumor monitoring twice a week ( ). Figure 7B ) and weight ( Figure 7C ).

[0174] Figures 8A-8C This demonstrates that basal cytokine levels in aCD79b CAR-T transduced cells do not increase in the absence of antigen or cytokine stimulation. Previously generated aCD79b CAR-T cells were seeded in triplicate plates at 50,000 CAR+ cells per well. The total T cell count per well was normalized across conditions by adding untransduced (UTD) cells. Culture supernatants were collected after overnight culture, and cytokine levels were quantified using MSD (V Plex Proinflammation Panel 1 [Human] Kit). INFγ, IL-2, and TNFα levels detected in the supernatants of 441-HL CAR-T, CD19 CAR-T, and UTD cells were plotted as mean (pg / mL) ± SEM for each donor.

[0175] Figures 9A-9B This demonstrates that 441-HL CAR-T cells do not exhibit abnormal basal proliferation or activation in the absence of antigen or cytokine stimulation. A five-day proliferation assay was performed in 441-HL CAR-T cells to screen for abnormal basal proliferation or activation. Cell Trace was used. TM After labeling with Violet (CTV) dye (5mM), CAR-T cells were diluted to 5×10⁻⁶. 5 Live CAR+ T cells / mL. Cells (100 μL) were then added to 96-well round-bottom plates where they were grown for five days in the absence of target cells or cytokine stimulation. Target-positive cells (CARNAVAL) and target-negative cells (K562) were similarly plated to obtain a 1:1 CAR+ effector:target (E:T) ratio and cultured under the same conditions. On day 5, cells were analyzed by flow cytometry gating to CD3, followed by CAR analysis. Proliferation in the five donors was determined using CTV dye dilution (Pacific Blue channel) and CD71 marker expression, respectively. Figure 9A ) and activation ( Figure 9B The percentage of CAR-T cells.

[0176] Figures 10A-10RDemonstrates antigen-specific cancer cell killing by 441-HL CAR-T cells in the presence of CD79b / CD19+ cells across all tested donors. The role of 441-HL CAR-T cells was tested using flow cytometry in groups of five CD79b / CD19+ cell lines (HBL-1, OCI-LY-10, CARNAVAL, WILL-2, and JEKO-1) and five CD79b / CD19– cell lines (K562, HLY-1, SU-DHL-1, HL-60, and JURKAT E6.1). K562 cells engineered to express CD79b were included as an additional control. After thawing and overnight incubation, cells were counted, and the percentage of CAR+ cells from each donor was normalized by adding untransduced cells. The normalized CAR-T cells were then counted at 5 x 10-1. 5 CAR+ cells / mL were resuspended to obtain an initial CAR+E:T ratio of 2.5:1. A total of eight 2-fold dilutions were prepared, and effector cells were seeded in 96-well plates (100 μL per well). Target cell lines were harvested, counted, and resuspended at 4 million cells / mL. They were then subjected to Cell Trace... TM Violet (CTV) was used for labeling and diluted to 2×10⁻⁶. 5 100 μL of labeled cells were added to a 96-well plate containing CAR-T cells, and the cells were incubated for 24 hours with the viability-fixing dye eFluor. TM 660 cells were stained. Tumor cell death was assessed by flow cytometry using the following methods: forward scattering and side scattering gating to identify cell populations; then LIVE / DEAD gating to identify viable cells; and finally, CTV+ tumor event gating to assess the number of viable cancer cells in each well. The percentage of cancer cell killing (%) was calculated by dividing the absolute number of viable cancer cells at each E:T ratio by the mean absolute number of viable cancer cells in wells with a 0:1 E:T ratio, and then multiplying by 100. Data were plotted as mean + / - SEM (3 separate experiments). Figures 10A-10C and Figures 10D-10F The image shows a combined diagram of five donors, specifically for CD79b / CD19+ and CD79b / CD19– cells. Figure 10G-Figure 10L and Figure 10M-Figure 10R The graphs showing individual killing curves for each of the five donors are presented for CD79b / CD19+ cells and CD79b / CD19– cells, respectively.

[0177] Figures 11A-11F It shows the use of The technology confirmed the specific killing effect of 441-HL CAR-T cells on antigen-positive cell lines. Utilizing... The killing kinetics of 441-HL CAR-T cells were evaluated in a group of two CD79b / CD19+ (HBL-1, OCI-LY-10) and two CD79b / CD19– (HLY-1, SU-DHL-1) mKATE2-expressing cell lines. After thawing and overnight incubation, cells were counted, and the percentage of CAR+ cells from each donor was normalized by adding untransduced cells. Normalized CAR-T cells were then counted and divided into groups of 5 x 10-1. 5 Resuspend the cells at a concentration of CAR+ cells / mL to obtain an initial CAR+E:T ratio of 2.5:1. Prepare a total of eight 2-fold dilutions and seed effector cells in 96-well plates (100 μL per well). Harvest the target cell lines, count them, and dilute them at 1 x 102 cells / mL. 5 Cells were resuspended at 100 μL / mL and seeded according to the plate layout (96-well plate; 100 μL per well). After mixing CAR-T cells and target cells, 80 μL from each well was dispensed twice into 384-well plates. The co-culture was then placed in... The ZOOM live-in-cell imaging system was used, with images automatically acquired every 4 hours in both phase and fluorescence channels using 4x objectives (single image) for 4 to 6 days. Target cell levels were quantified based on mKATE2 red fluorescent protein expression. To quantify cancer cell killing over time, the mean area under the curve (AUC) for each replicate was derived to GraphPad Prism and for each condition was derived. After normalization to the untreated control, the E:T ratio was plotted as a dose-response relationship against the AUC value. Dose-response plots were generated for five donors (two independent experiments) with pooled values ​​(mean ± SEM) or individual values. Figure 11A and Figure 11B The image shows a merged plot for CD79b / CD19+ cells and CD79b / CD19– cells, respectively. Figures 11C-11D and Figures 11E-11F The graphs showing individual killing curves for each donor are presented for CD79b / CD19+ cells and CD79b / CD19– cells, respectively.

[0178] Figures 12A-12JThe antigen-specific production of pro-inflammatory cytokines in 441-HL CAR-T cells was demonstrated. Supernatants were collected from four CD79b / CD19+ cell lines (HBL-1, OCI-LY-10, CARNAVAL, WILL-2) and two CD79b / CD19– cell lines (HLY-1 and SU-DHL-1) during flow cytometry-based killing assays and tested using MesoScale Discovery (MSD). Data analysis was performed and the results for each cytokine were plotted as individual values ​​for each of the five donors (two independent experiments) and as mean values ​​for each treatment group. Figures 12A-12D The figure shows a graph of the levels (pg / mL) of INFγ, IL-2, TNFα, and IL-6 detected in the supernatant of 441-HL CAR-T, CD19 CAR-T, and UTD cells collected for each donor, as well as a pooled graph across donors (mean ± SEM). Figures 12E-12H The figure shows a graph of IL-4, IL-1β, IL10 and IL12p70 (pg / mL) detected in the supernatant of 441-HL CAR-T, CD19 CAR-T and UTD cells collected for each donor, as well as a pooled graph across donors (mean ± SEM). Figures 12I-12J The figure shows a graph of IL-13 and IL-8 (pg / mL) detected in the supernatant of 441-HL CAR-T, CD19CAR-T and UTD cells collected for each donor, as well as a pooled graph across donors (mean ± SEM).

[0179] Figures 13A-13C This study demonstrates the dose-dependent inhibition of tumor growth by CD79b CAR-T cells in a CARNAVAL xenograft model. Figure 13A This diagram illustrates an experimental paradigm used to investigate the in vivo efficacy of CD79b CAR-T cells in a CARNAVAL xenograft model. On day 0, 5 x 10⁻⁶ CARNAVAL cells in logarithmic growth phase were subcutaneously implanted into NOD / scid / IL-2Rg- / - (NSG) mice. 5 (Number of tumors in each group). When the average tumor volume in the group reaches approximately 50 mm. 3 -100mm 3 Mice were intravenously injected with multiple doses of CAR+T cells as described in this article (14 days post-implantation). Tumor volume and body weight were recorded, and blood samples were collected periodically. Figure 13B The figure shows the average tumor volume (mm²) over the number of days following tumor implantation. 2 ±SEM). Figure 13C The figure shows the average percentage change in body weight (% ± SEM) over the number of days following tumor implantation. Detailed Implementation

[0180] An exemplary implementation scheme is described below:

[0181] This disclosure provides chimeric antigen receptors (CARs) that target differentiation cluster 79B protein (CD79b) , cells containing such CARs, and methods of treating cancers (e.g., B-cell lymphoma) using the CARs described herein.

[0182] The CAR of the present invention is antigen-specific to CD79b. As used herein, the phrases "antigen-specific" and "provides an antigen-specific response" mean that the CAR can specifically bind to and immunely recognize the antigen, such that the binding of the CAR to the CD79b antigen triggers an immune response. Methods for testing the antigen specificity of the CAR and its ability to recognize target cells are known in the art.

[0183] This disclosure also provides related nucleic acids, recombinant expression vectors, host cells, cell populations, antibodies or antigen-binding portions thereof, and pharmaceutical compositions related to the CAR of the present invention.

[0184] Several aspects of the invention are described below with reference to embodiments for illustrative purposes only. It should be understood that numerous specific details, relationships, and methods are set forth to provide a comprehensive understanding of the invention. However, those skilled in the art will readily recognize that the invention can be practiced without one or more specific details, or can be practiced using other methods, schemes, reagents, cell lines, and animals. The invention is not limited to the order in which actions or events are shown, as some actions may occur in a different order and / or simultaneously with other actions or events. Furthermore, not all shown actions, steps, or events are necessary for implementing the method according to the invention. Many techniques and procedures described or referenced herein are well known to those skilled in the art and are generally adopted by those skilled in the art using conventional methods.

[0185] Unless otherwise specified, all technical terms, symbols, and other scientific terms or specialized expressions used herein are intended to have the meaning commonly understood by one of ordinary skill in the art to which this invention pertains. In some instances, for clarity and / or ease of reference, terms are defined herein with their commonly understood meanings, and these definitions should not necessarily be construed as indicating a significant difference from the meanings commonly understood in the art. It should also be understood that terms (such as those defined in common dictionaries) should be interpreted as having meanings consistent with their meanings in the relevant field context and / or as otherwise defined herein.

[0186] definition

[0187] When a list is provided, unless otherwise indicated, it should be understood that each individual element in the list and each combination of the list is a separate implementation. For example, a list of implementations presented as “A, B or C” will be understood to include implementations “A”, “B”, “C”, “A or B”, “A or C”, “B or C”, or “A, B or C”.

[0188] It should be understood that the terminology used herein is for the purpose of describing specific implementations only and is not intended to be restrictive. As used herein, unless the context clearly indicates otherwise, the indefinite articles “a,” “an,” and “the” should be understood to include plural references.

[0189] The transitional terms “comprising,” “substantially consisting of,” and “consisting of” are intended to imply their accepted meaning in patent terminology; that is, (i) “comprising” is synonymous with “including,” “containing,” or “characterized by,” and is inclusive or open at the end, and does not exclude additional, unlisted elements or method steps; (ii) “consisting of” excludes any element, step, or component not specified in the claims; and (iii) “substantially consisting of” limits the scope of the claims to the specified material or step “and material or step that does not substantially affect the essential and novel features of the invention protected by the claims.” Embodiments described with the phrase “comprising” (or its equivalents) are also provided, as are those described independently with “consisting of” and “substantially consisting of”.

[0190] The term "about" or "approximately" includes a range of values ​​that are statistically significant. Such a range may be within orders of magnitude of a given value or range, preferably within 50%, more preferably within 20%, still more preferably within 10%, and even more preferably within 5%. The permissible variation covered by the term "about" or "approximately" depends on the specific system being studied and can be readily understood by one of ordinary skill in the art.

[0191] "Activation" or "stimulation" refers to the induction of a change in the biological state of a cell, through which cells (e.g., T cells and NK cells) express activation markers, produce cytokines, proliferate, and / or become cytotoxic to target cells. All of these changes can be generated by primary stimulus signals. Co-stimulatory signals can amplify the amplitude of primary signals and inhibit cell death following initial stimulation, thereby producing a more persistent state of activation and thus greater cytotoxic capacity. "Co-stimulatory signals" refer to signals that, in combination with primary signals (such as TCR / CD3 linkages), lead to the upregulation or downregulation of T cell and / or NK cell proliferation and / or key molecules.

[0192] "Bispecificity" refers to a molecule (such as an antibody) that specifically binds to two different antigens or two different epitopes within the same antigen. Bispecific molecules may be cross-reactive to other related antigens, for example, to the same antigen from other species (homologous) (such as humans or monkeys, such as cynomolgus macaques or pan troglodytes), or they may bind to epitopes shared between two or more different antigens.

[0193] As used herein, the term "chimeric antigen receptor" or "CAR" is defined as a cell surface receptor comprising an extracellular target-binding domain, a transmembrane domain, and an intracellular signaling domain, all of which are present together non-naturally on a single protein. This specifically includes receptors in which the extracellular domain and the intracellular signaling domain are present together non-naturally on a single receptor protein. The chimeric antigen receptor of the present invention is primarily intended for use with lymphocytes such as T cells and natural killer (NK) cells.

[0194] The term "encoding" refers to the inherent property of a specific nucleotide sequence in a polynucleotide (such as a gene, cDNA, or mRNA) to serve as a template for the synthesis of other polymers and macromolecules in biological processes, having defined nucleotide sequences (e.g., rRNA, tRNA, and mRNA) or defined amino acid sequences and the resulting biological properties. Therefore, if the transcription and translation of mRNA corresponding to a gene produces a protein in a cell or other biological system, then the gene, cDNA, or RNA encodes that protein. Both the coding strand (whose nucleotide sequence is identical to the mRNA sequence) and the non-coding strand (which serves as a template for gene or cDNA transcription) can be said to encode that protein, or other products of that gene or cDNA.

[0195] Unless otherwise specified, "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate forms of each other and encode the same amino acid sequence. The phrase "nucleotide sequence" encoding a protein or RNA may also include introns to such an extent that the nucleotide sequence encoding that protein may contain introns in some forms.

[0196] The term "expression vector" refers to a vector containing a recombinant polynucleotide that includes an expression control sequence operatively linked to a nucleotide sequence to be expressed. The expression vector contains sufficient cis-acting elements for expression; other elements for expression may be supplied by the host cell or by an in vitro expression system. Expression vectors include all those known in the art, including clomiphene citrates, plasmids (e.g., naked plasmids or plasmids contained in liposomes), and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) bound to the recombinant polynucleotide.

[0197] "Heterologous" refers to two or more polynucleotides or two or more polypeptides that do not share a common relationship with each other in nature.

[0198] "Heteronucleotides" refer to non-naturally occurring polynucleotides that encode two or more neoantigens as described in this article.

[0199] "Heterogeneous polypeptide" refers to a polypeptide that is not naturally occurring and contains two or more neoantigen polypeptides as described in this article.

[0200] "Host cell" refers to any cell containing heterologous nucleic acid. An exemplary heterologous nucleic acid is a vector (e.g., an expression vector).

[0201] The terms “T cell” and “T lymphocyte” are interchangeable and used synonymously herein. As used herein, T cells include thymocytes, naive T lymphocytes, immature T lymphocytes, mature T lymphocytes, resting T lymphocytes, or activated T lymphocytes. T cells can be T helper (Th) cells, such as T helper 1 (Th1) or T helper 2 (Th2) cells. T cells can be helper T cells (HTL; CD4+ T cells), CD4+ T cells, cytotoxic T cells (CTL; ​​CD8+ T cells), tumor-infiltrating cytotoxic T cells (TIL; CD8+ T cells), CD4+CD8+ T cells, or any other subset of T cells. Other exemplary populations of T cells suitable for a particular implementation include naive T cells and memory T cells. Also included is “NKT cells,” which refers to a specialized population of T cells that expresses the semi-invariant αβ T cell receptor but also expresses multiple molecular markers commonly associated with NK cells, such as NK1.1. NKT cells include NK1.1+ and NK1.1- cells, as well as CD4+, CD4-, CD8+, and CD8- cells. The unique feature of the TCR on NKT cells is that it recognizes glycolipid antigens presented by the MHC I-like molecule CD1d. Because NKT cells can produce cytokines that promote inflammation or immune tolerance, they can have protective or destructive effects. Also included are "γ-δT cells (γδT cells)," a specialized subset of T cells with unique TCRs on their surface. Unlike most T cells, where the TCR consists of two glycoprotein chains named α-TCR and β-TCR, the TCR in γδT cells consists of both γ- and δ-chains. γδT cells can play a role in immune surveillance and immune regulation and have been found to be an important source of IL-17 and induce strong CD8+ cytotoxic T cell responses. Also included are "regulatory T cells" or "Tregs," which are T cells that suppress abnormal or excessive immune responses and play a role in immune tolerance. Treg cells are typically Foxp3-positive CD4+ T cells, and may also include Foxp3-negative regulatory T cells that produce IL-10 CD4+ T cells.

[0202] The terms “natural killer cell” and “NK cell” are interchangeable and used synonymously herein. As used herein, NK cells refer to differentiated lymphocytes with a CD16+CD56+ and / or CD57+TCR- phenotype. NK cells are characterized by their ability to bind to and kill cells that do not express “self” MHC / HLA antigens by activating specific cytolytic enzymes, to kill tumor cells or other diseased cells expressing ligands of the NK activation receptor, and to release protein molecules called cytokines that stimulate or suppress immune responses.

[0203] As used herein, the term "antigen" refers to any reagent molecule (e.g., protein, peptide, polysaccharide, glycoprotein, glycolipid, nucleic acid, parts thereof, or combinations thereof) capable of being bound by T-cell receptors. Antigens can also elicit an immune response. Examples of an immune response may involve, but are not limited to, antibody production, or activation of specific immune-active cells, or both. Those skilled in the art will understand that antigens do not necessarily need to be encoded by "genes." It will be apparent that antigens can be generated synthetically or derived from biological samples, or can be macromolecules other than polypeptides. Such biological samples may include, but are not limited to, tissue samples, tumor samples, cells or fluids containing other biological components, organisms, protein / antigen subunits, killed or inactivated whole cells, or lysates.

[0204] An "antigen-binding fragment" or "antigen-binding domain" refers to the portion of a protein that binds to an antigen. Antigen-binding domains can be synthetic, enzymatically obtained, or genetically engineered polypeptides, and include antigen-binding portions of immunoglobulins such as VH, VL, VH and VL, Fab, Fab', F(ab')2, Fd, and Fv fragments; domain antibodies (dAbs) consisting of a VH domain or a VL domain; shark variable IgNAR domains; humped VH domains; VHH domains; minimal recognition units consisting of amino acid residues of CDRs of antibody mimics such as FR3-CDR3-FR4, HCDR1, HCDR2, and / or HCDR3, and LCDR1, LCDR2, and / or LCDR3; alternative scaffolds for antigen binding; and multispecific proteins containing antigen-binding fragments. Antigen-binding fragments (such as VH and VL) can be linked together via synthetic linkers to form various types of monoclonal antibody designs. In those cases where the VH and VL domains are expressed by separate single chains, the VH / VL domains can be paired intramolecularly or intermolecularly to form monovalent antigen-binding sites, such as single-chain Fv (scFv) or double-chain antibodies. Antigen-binding fragments can also be conjugated to other antibodies, proteins, antigen-binding fragments, or alternative scaffolds, which can be monospecific or multispecific, engineered to contain bispecific and multispecific proteins.

[0205] The term "antibody" refers to monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, chimeric antibodies, single-chain Fv (scFv), single-chain antibodies, Fab fragments, F(ab') fragments, disulfide-linked Fv (sdFv), intracellular antibodies, microantibodies, biantibodies, and anti-idiotypic (anti-Id) antibodies (including, for example, anti-Id antibodies against antigen-specific TCRs), and epitope-binding fragments of any of the above antibodies. The term "antibody" also refers to covalent biantibodies, such as those disclosed in U.S. Patent Application Publication 2007 / 0004909, and Ig-DARTS, such as those disclosed in U.S. Patent Application Publication 2009 / 0060910. Antibodies that can be used as TCR-binding molecules include immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, i.e., molecules containing antigen-binding sites. Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgM1, IgM2, IgA1, and IgA2), or subclass.

[0206] "Human antibody" refers to an antibody optimized to produce a minimal immune response when administered to a human subject. The variable region of a human antibody is derived from a human immunoglobulin sequence. If a human antibody contains a constant region or a portion of a constant region, that constant region is also derived from a human immunoglobulin sequence. If the variable region of a human antibody is obtained using a system that uses human germline immunoglobulins or rearranged immunoglobulin genes, the human antibody contains both heavy-chain and light-chain variable regions "derived" from human-origin sequences. Exemplary systems of this kind are human immunoglobulin gene libraries displayed on bacteriophages, and transgenic non-human animals, such as mice or rats carrying human immunoglobulin loci. Due to differences between the systems used to obtain human antibodies and human immunoglobulin loci, the introduction of somatic mutations, or the intentional substitution of elements introduced into the frame or CDR, or both, "human antibodies" typically contain amino acid differences compared to immunoglobulins expressed in humans. Typically, the amino acid sequence of a “human antibody” has at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the amino acid sequence encoded by a human germline immunoglobulin gene or rearranged immunoglobulin gene. In some cases, a “human antibody” may contain a common frame sequence derived from human frame sequence analysis (e.g., as described in Knappik et al., (2000) J Mol Biol 296:57-86), or a synthetic HCDR3 bound to a human immunoglobulin gene library displayed on a bacteriophage (e.g., as described in Shi et al., (2010) J Mol Biol 397:385-96 and International Patent Publication WO2009 / 085462). The definition of "human antibody" does not include at least one antibody with a CDR derived from a non-human species.

[0207] "Humanized antibody" refers to an antibody in which at least one CDR is derived from a non-human species and at least one frame is derived from a human immunoglobulin sequence. Humanized antibodies may contain substitutions in the frame such that the frame may not be an exact copy of the expressed human immunoglobulin or the germline gene sequence of a human immunoglobulin.

[0208] "Specific binding" or "binding" refers to the binding of protein molecules to antigens or epitopes within antigens with a greater affinity than to other antigens. Typically, the binding of a protein molecule to an antigen or epitope within an antigen occurs at an equilibrium dissociation constant (K). D It is approximately 1x10 -7 M or lower, for example, about 5x10 -8 M or lower, approximately 1x10 -8 M or lower, approximately 1x10 -9 M or lower, approximately 1x10 -10 M or lower, approximately 1x10-11 M or lower or approximately 1x10 -12 M or lower, usually K D Compared to its binding to non-specific antigens (such as BSA, casein), K D At least one hundred times lower. In the context of the CD79b antigen described herein, "specific binding" refers to the binding of a protein molecule to the CD79b antigen, without detectable binding to the wild-type protein of which the neoantigen is a variant.

[0209] The term "host cell" refers to any cell containing heterologous nucleic acid. Heterologous nucleic acid can be a vector (e.g., an expression vector). For example, a host cell can be a cell from any organism that is selected, modified, transformed, grown, used, or manipulated in any way for the purpose of producing substances through the cell, such as expressing genes, DNA or RNA sequences, proteins, or enzymes through the cell. A suitable host can be determined. For example, a host cell can be selected based on the vector backbone and the desired outcome. For instance, plasmids or granules can be introduced into prokaryotic host cells to replicate several types of vectors. Bacterial cells such as, but not limited to, DH5α, JM109, and KCB... Competent cells and SOLOPACK gold cells can be used as host cells for vector replication and / or expression. Additionally, bacterial cells such as *Escherichia coli* LE392 can be used as host cells for bacteriophage viruses. Eukaryotic cells that can be used as host cells include, but are not limited to, yeast (e.g., YPH499, YPH500, and YPH501), insects, and mammals. Examples of mammalian eukaryotic host cells used for vector replication and / or expression include, but are not limited to, HeLa, NIH3T3, Jurkat, 293, COS, CHO, Saos, and PC12.

[0210] The host cells disclosed herein include T cells and natural killer cells, which contain DNA or RNA sequences encoding CARs and express CARs on their cell surface. These host cells can be used to enhance T cell activity, natural killer cell activity, and to treat cancer and autoimmune diseases.

[0211] The term "proliferation" refers to an increase in cell division (symmetrical or asymmetrical cell division). The term "expansion" refers to the result of cell division and cell death.

[0212] The term "differentiation" refers to methods that reduce the efficiency or proliferation of cells or bring cells into a more restricted state of development.

[0213] The term "expression" refers to the permission or initiation of the production of information from a gene or DNA sequence, such as the production of proteins by activating cellular functions involved in the transcription and translation of the corresponding gene or DNA sequence. DNA sequences are expressed in or through cells to form "expression products," such as proteins. It is claimed that the expression products themselves, such as the resulting proteins, can also be "expressed" by cells. Expression products can be characterized as intracellular, extracellular, or transmembrane.

[0214] The term "transfection" refers to the introduction of "foreign" (i.e., foreign or extracellular) nucleic acids into a cell using recombinant DNA technology. The term "genetic modification" refers to the introduction of a "foreign" (i.e., foreign or extracellular) gene, DNA, or RNA sequence into a host cell, causing the host cell to express the introduced gene or sequence to produce the desired substance, typically a protein or enzyme encoded by the introduced gene or sequence. The introduced gene or sequence, also referred to as a "clone" or "foreign" gene or sequence, can include regulatory or control sequences operatively linked to a polynucleotide encoding a chimeric antigen receptor, such as initiation, termination, promoter, signaling, secretion, or other sequences used by cellular genetic mechanisms. Genes or sequences can include non-functional or non-functional sequences. The host cell that receives and expresses the introduced DNA or RNA has been "genetically engineered." The DNA or RNA introduced into the host cell can originate from any source, including cells of the same genus or species as the host cell, or from a different genus or species.

[0215] The term "transduction" refers to the introduction of foreign nucleic acids into cells using a viral vector.

[0216] The term "regulatory element" refers to any cis-acting gene element that controls some aspect of the expression of a nucleic acid sequence. In some embodiments, the term "promoter" essentially includes the minimum sequence required to initiate transcription. In some embodiments, the term "promoter" includes the sequence that initiates transcription, and additionally includes sequences that can upregulate or downregulate transcription, often referred to as "enhancer elements" and "repressor elements," respectively.

[0217] As used herein, the terms “operationally linked,” “operationally linked,” and similar phrases, when used to refer to nucleic acids or amino acids, refer to the operational linking of nucleic acid sequences or amino acid sequences that are functionally related to each other. For example, an operationally linked promoter, enhancer element, open reading frame, 5' and 3' UTR, and terminator sequence leads to the precise production of a nucleic acid molecule (e.g., RNA). In some embodiments, an operationally linked nucleic acid element leads to transcription of the open reading frame and ultimately the production of a polypeptide (i.e., expression of the open reading frame). As another example, an operationally linked peptide is a peptide in which functional domains are spaced appropriately apart to confer the intended function on each domain.

[0218] The term "treatment" refers to a therapeutic process in which the treatment will slow (alleviate) undesired physical changes or disease, or provide beneficial or desired clinical outcomes during treatment. Beneficial or desired clinical outcomes include symptom reduction, disease severity decrease, stable (i.e., no worsening) state of disease, delay or slowing of disease progression, improvement or mitigation of disease status, and / or remission (whether partial or complete), whether detectable or undetectable. "Treatment" can also mean extended survival compared to the expected survival of a subject without treatment. Subjects requiring treatment include those who already have undesired physical changes or disease, and those who are predisposed to developing such changes or disease.

[0219] As used herein, the term "subject" refers to an animal. The terms "subject" and "patient" are used interchangeably in this document when referring to a subject. Therefore, "subject" includes a person who is a patient receiving treatment for or preventing a disease. The methods described herein can be used to treat animal subjects belonging to any classification. Examples of such animals include mammals. Mammals include, but are not limited to, mammals of the order Rodentia (such as mice and hamsters) and mammals of the order Logomorpha (such as rabbits). Mammals can be from the order Carnivora, including felines (cats) and canines (dogs). Mammals can be from the order Artiodactyla, including bovids (cows) and suidae (pigs), or perissodactyla, including equines (horses). Mammals can be from the orders Primate, Ceboid, or Simoid (monkeys), or Anthropoid (humans and apes). In one embodiment, the mammal is a human.

[0220] The terms "enhancement," "promotion," "increase," "amplification," or "improvement" generally refer to the ability of the composition, as intended herein, to produce, initiate, or cause a greater physiological response (i.e., downstream action) compared to the response induced by the mediator or control molecule / composition. Measurable physiological responses may include increased T-cell expansion, activation, effector function, persistence, and / or increased cancer cell killing capacity, as well as responses readily apparent from the understanding in the art and the description herein. In some embodiments, the amount of "increase" or "enhancement" may be a "statistically significant" amount and may include an increase of 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, or more (e.g., 500, 1000) in response compared to the mediator or control composition (including all integers and decimals between and above 1, such as 1.5, 1.6, 1.7, 1.8, etc.).

[0221] "Reduced," "decreased," "less," "less," or "weakened" generally refers to the ability of the composition contemplated herein to produce, initiate, or induce a smaller physiological response (i.e., downstream effect) compared to the response induced by the mediator or control molecule / composition. In some embodiments, the amount of "reduced" or "less" can be a "statistically significant" amount and can include a reduction of 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, or more times (e.g., 500, 1000 times) compared to the response induced by the mediator, control composition (reference response), or response in a particular cell lineage (e.g., 500, 1000 times) (including all integers and decimals in between and above 1, such as 1.5, 1.6, 1.7, 1.8, etc.).

[0222] "Cancer" refers to a wide variety of diseases characterized by the uncontrolled growth of abnormal cells in the body. Uncontrolled cell division and growth lead to the formation of malignant tumors that invade adjacent tissues and can also metastasize to distant parts of the body via the lymphatic system or bloodstream. "Cancer" or "cancer tissue" can include tumors.

[0223] "Relapse" refers to the recurrence of the disease or signs and symptoms of the disease after a period of improvement following previous treatment with medication.

[0224] "Treatment refractory" refers to a disease that does not respond to treatment. A treatment refractory disease may be resistant to treatment before or at the start of treatment, or it may become resistant during treatment.

[0225] "Tumor cells" or "cancer cells" refer to cancerous, precancerous, or transformed cells in vivo, in vitro, or in tissue cultures that exhibit spontaneous or induced phenotypic changes. These changes do not necessarily involve the uptake of new genetic material. However, transformation can occur due to infection with transforming viruses and the binding of new genomic nucleic acids, the uptake of exogenous nucleic acids, or it can occur spontaneously or after exposure to carcinogens, thereby causing mutations in endogenous genes. Examples of transformation / cancer include morphological changes in vitro, in vivo, and in vitro in suitable animal hosts (such as nude mice), cell immortalization, abnormal growth control, lesion formation, proliferation, malignancy, regulation of tumor-specific marker levels, invasion, and tumor growth.

[0226] The term "effective" when applied to dosage or amount means an amount of a compound or pharmaceutical composition sufficient to produce the desired activity when administered to a subject in need. Note that when a combination of active ingredients is administered, the effective amount of the combination may or may not include the amount of each ingredient that would be effective if administered alone. The exact amount required will vary from subject to subject, depending on the subject's species, age and general condition, the severity of the condition being treated, one or more specific medications used, the mode of administration, etc.

[0227] The terms “prevent,” “preventing,” “prevention,” or “prophylaxis” refer to the prevention of a disease or condition from occurring in a subject.

[0228] The term “therapeutic effective dose” or “effective dose” is used interchangeably herein and refers to the amount that effectively achieves the desired therapeutic outcome at the required dose and time period. Therapeutic effective doses can vary depending on factors such as an individual’s disease state, age, sex, and weight, as well as the ability of the therapeutic agent or combination of therapeutic agents to elicit the desired response in the individual. Exemplary indicators of an effective therapeutic agent or combination of therapeutic agents include, for example, improvements in the patient’s health status, reduction in tumor burden, inhibition or slowing of tumor growth, and / or the absence of metastasis of cancer cells to other parts of the body.

[0229] The phrase “pharmaceutical acceptable” used in conjunction with the compositions described herein means that the molecular entities and other components of such compositions are physiologically tolerable and generally do not produce adverse effects when administered to mammals (e.g., humans). Preferably, the term “pharmaceutical acceptable” means a substance approved by a federal or state regulatory agency or listed in the United States Pharmacopeia or other recognized pharmacopoeia for use in mammals, and more specifically, in humans.

[0230] The term “protein” as used herein encompasses all kinds of naturally occurring and synthetic proteins, including protein fragments of all lengths, fusion proteins, and modified proteins, including but not limited to glycoproteins and all other types of modified proteins (e.g., those modified by phosphorylation, acetylation, myristoylation, palmitoylation, glycosylation, oxidation, formylation, amidation, polyglutamylation, ADP ribosylation, PEGylation, biotinylation, etc.).

[0231] Unless otherwise stated, the terms “nucleic acid,” “nucleotide,” and “polynucleotide” cover both DNA and RNA. “Nucleic acid sequence” or “nucleotide sequence” means a nucleic acid sequence that encodes an amino acid; these terms may also refer to a nucleic acid sequence that includes portions encoding any amino acid as a clone, including any amino acid encoded by a linker.

[0232] "Isolated" refers to a homogeneous group of molecules (such as synthetic polynucleotides or polypeptides) that have been substantially isolated and / or purified from other components of the system that produced the molecules (such as recombinant cells), as well as proteins that have undergone at least one purification or isolation step. "Isolated" also refers to molecules that are substantially free of other cellular material and / or chemicals, and encompasses molecules isolated to higher purities (such as 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% purity).

[0233] The term "carrier" refers to a diluent, excipient, excipient, or medium that is applied together with a compound. Such drug carriers can be sterile liquids, such as water and oils, including those derived from petroleum, animals, plants, or synthetic sources, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Water or aqueous solutions, saline solutions, glucose solutions, and glycerol solutions are preferred as carriers, particularly for injectable solutions. Alternatively, carriers can be solid dosage form carriers, including, but not limited to, one or more of binders (for compressed pellets), flow aids, encapsulating agents, flavoring agents, and coloring agents. Suitable drug carriers are described in EWMartin's "Pharmaceutical Sciences".

[0234] "Differentiation cluster 79B protein" or "CD79b" refers to a known protein, also known as B cell-specific glycoprotein B29, Ig-β, or AGM6. The B lymphocyte antigen receptor is a multimeric complex comprising antigen-specific components non-covalently associated with Ig-α and Ig-β, surface immunoglobulins (Ig). CD79b is the Ig-β protein of the B cell antigen component. All CD79b isotypes and variants are covered under the term "CD79b". Amino acid sequences of various isotypes can be retrieved from GenBank accessions AAH32651.1, EAW94232.1, AAH02975.2, NP_000617.1, and NP_001035022.1. The amino acid sequence of the full-length CD79b is shown below. This sequence includes an extracellular domain (residues 29-159) and a cytoplasmic domain (residues 181-229).

[0235] MARLALSPVPSHWMVALLLLLSAEPVPAARSEDRYRNPKGSACSRIWQSPRFIARKRGFTVKMHCYMNSASGNVSWLWKQEMDENPQQLKLEKGRMEESQNESLATLTIQGIRFED NGIYFCQQKCNNTSEVYQGCGTELRVMGFSTLAQLKQRNTLKDGIIMIQTLLIILFIIVVPIFLLLDKDDSKAGMEEDHTYEGLDIDQTATYEDIVTLRTGEVKWSVGEHPGQE(SEQ ID NO:282)

[0236] Chimeric antigen receptor

[0237] This invention relates generally to the use of genetically modified T cells to stably express desired chimeric antigen receptors. Chimeric antigen receptors (CARs) are artificially constructed hybrid proteins or polypeptides containing an antigen-binding domain of an antibody (scFv) linked to a T cell signaling domain. CARs can be characterized by their ability to specifically and reactivity redirect T cells to selected targets in a non-MHC-restricted manner, thereby utilizing the antigen-binding properties of monoclonal antibodies. Non-MHC-restricted antigen recognition confers the ability of CAR-expressing T cells to recognize antigens independently of antigen processing, thus bypassing major mechanisms of tumor escape. Furthermore, when expressed in T cells, CARs advantageously do not dimerize with the α and β chains of the endogenous T cell receptor (TCR).

[0238] The CAR described herein provides a recombinant polypeptide construct comprising at least an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain (also referred to herein as a "cytoplasmic signaling domain"), the intracellular signaling domain including functional signaling domains derived from stimulatory molecules as defined below. T cells expressing CAR are referred to herein as CAR T cells, CAR-T cells, or CAR-modified T cells, and these terms are used interchangeably herein. These cells can be genetically modified to stably express antibody-binding domains on their surface, thereby conferring novel MHC-independent antigen specificity.

[0239] In some cases, T cells are genetically modified to stably express a CAR that combines the antigen-recognition domain of a specific antibody with the intracellular domain of a CD3-ζ chain or an FcγRI protein into a single chimeric protein. In one embodiment, the stimulating molecule is a ζ chain associated with a T cell receptor complex.

[0240] As used herein, the term "intracellular signaling domain" refers to the intracellular portion of a molecule. This functional portion of a protein functions by transmitting information within the cell to regulate cellular activity via defined signaling pathways by generating second messengers, or to act as an effector in response to such messengers. Intracellular signaling domains generate signals that promote the function of immune effectors in CAR-containing cells (e.g., CAR-T cells). Examples of immune effector functions (e.g., in CAR-T cells) include cytolytic activity and cofactor activities, including the secretion of cytokines.

[0241] In one embodiment, the intracellular signaling domain may include a primary intracellular signaling domain. Example primary intracellular signaling domains include those derived from molecules responsible for primary or antigen-dependent stimulation. In one embodiment, the intracellular signaling domain may include a co-stimulatory intracellular domain. Example co-stimulatory intracellular signaling domains include those derived from molecules responsible for co-stimulatory signals or antigen-independent stimulation. For example, in the case of CAR-T, the primary intracellular signaling domain may contain a cytoplasmic sequence of a T cell receptor, and the co-stimulatory intracellular signaling domain may contain a cytoplasmic sequence derived from a co-receptor or co-stimulatory molecule.

[0242] Primary intracellular signal transduction domains may contain signal transduction motifs, referred to as immune receptor tyrosine-based activation motifs or ITAMs. Examples of primary cytoplasmic signal transduction sequences containing ITAMs include, but are not limited to, those derived from CD3-ζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD5, CD22, CD79a, CD79b, and CD66d, DAP10, and DAP12.

[0243] The term “ζ” or alternatively “ζ chain,” “CD3-ζ,” or “TCR-ζ” is defined as a protein provided with GenBank accession number BAG36664.1, or an equivalent residue from a non-human species (e.g., mouse, rabbit, primate, rodent, monkey, ape, etc.), and “ζ-stimulatory domain” or alternatively “CD3-ζ-stimulatory domain” or “TCR-ζ-stimulatory domain” is defined as an amino acid residue from the cytoplasmic domain of the ζ chain sufficient to functionally transmit the initial signal necessary for T cell activation. In one aspect, the cytoplasmic domain of ζ contains residues 52 to 164 of GenBank accession number BAG36664.1, or equivalent residues from non-human species (e.g., mouse, rodent, monkey, ape, etc.) of its functional ortholog. In one aspect, the “ζ-stimulatory domain” or “CD3-ζ-stimulatory domain” is a sequence provided as SEQ ID NO:28, or a sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:41.

[0244] The term "co-stimulatory molecule" refers to a homologous binding partner on a T cell that specifically binds to a co-stimulatory ligand, thereby mediating a co-stimulatory response in the T cell, such as, but not limited to, proliferation. Co-stimulatory molecules are cell surface molecules other than antigen receptors or their ligands that are required for an effective immune response. Co-stimulatory molecules include, but are not limited to, MHC class 1 molecules, BTLA and Toll ligand receptors, as well as OX40, CD2, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a / CD18), and 4-1BB (CD137).

[0245] The intracellular signal transduction domain of a costimulatory molecule can be the intracellular portion of that molecule. Costimulatory molecules can be represented by the following protein families: TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signal transduction lymphocyte-activating molecules (SLAM proteins), and activated NK cell receptors. Examples of such molecules include CD27, CD28, 4-1BB (CD137), OX40, GITR, CD30, MyD88, CD40, ICOS, BAFFR, HVEM, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3, and ligands that specifically bind to CD83, etc.

[0246] Intracellular signal transduction domains can contain the entire intracellular portion of their source molecule or the entire natural intracellular signal transduction domain, or a functional fragment thereof.

[0247] The term “4-1BB” or alternatively “CD137” refers to a member of the TNFR superfamily having the amino acid sequence provided as GenBank accession number AAA62478.2, or equivalent residues from non-human species (e.g., mice, rodents, monkeys, apes, etc.); and the “4-1BB co-stimulatory domain” is defined as amino acid residues 214 to 255 of GenBank accession number AAA62478.2, or equivalent residues from non-human species (e.g., mice, rodents, monkeys, apes, etc.). In one aspect, the “4-1BB co-stimulatory domain” or the “CD137 co-stimulatory domain” is a sequence provided as SEQ ID NO:27, or an equivalent residue from a non-human species (e.g., mouse, rodent, monkey, ape, etc.), or a sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:40.

[0248] In one embodiment, a transmembrane domain that naturally associates with a domain in the CAR is used. In another embodiment, the transmembrane domain may be selected or modified by amino acid substitution to prevent such domains from binding to transmembrane domains of the same or different surface membrane proteins, thereby minimizing interactions with other members of the receptor complex. In an example embodiment, the transmembrane domain includes a CD8α hinge domain.

[0249] In some embodiments, the cytoplasmic signaling domain further comprises one or more functional signaling domains derived from at least one co-stimulatory molecule as defined herein. In one embodiment, the co-stimulatory molecule is selected from 4-1BB (i.e., CD137), CD27, CD3-ζ, and / or CD28. CD28 is a T cell marker important in T cell co-stimulation. CD27 is a member of the tumor necrosis factor receptor superfamily and acts as a co-stimulatory immune checkpoint molecule. 4-1BB delivers a potent co-stimulatory signal to T cells, thereby promoting T lymphocyte differentiation and enhancing long-term T lymphocyte survival. CD3-ζ associates with the TCR to generate a signal and contains an immune receptor tyrosine-based activation motif (ITAM). In another embodiment, the co-stimulatory molecule is MyD88 or CD40.

[0250] In one embodiment, the CAR comprises an intracellular hinge domain and an intracellular T-cell receptor signaling domain, wherein the intracellular hinge domain comprises CD8, and the intracellular T-cell receptor signaling domain comprises CD28, 4-1BB, and CD3-ζ. In another embodiment, the CAR comprises an intracellular hinge domain and an intracellular T-cell receptor signaling domain, wherein the intracellular T-cell receptor signaling domain comprises CD28, 4-1BB, and CD3-ζ, wherein the hinge domain comprises all or part of the extracellular region of CD8, CD4, or CD28; all or part of the antibody constant region; and all or part of the FcyRIIIa receptor, IgG hinge, IgM hinge, IgA hinge, IgD hinge, IgE hinge, or Ig hinge. The IgG hinge may be derived from IgG1, IgG2, IgG3, IgG4, IgM1, IgM2, IgA1, IgA2, IgD, IgE, or a chimera thereof.

[0251] The CAR described herein provides a recombinant polypeptide construct comprising at least an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain (also referred to herein as a "cytoplasmic signal transduction domain"), the intracellular signal transduction domain including, for example, functional signal transduction domains derived from stimulatory molecules as defined below.

[0252] In one embodiment, the CAR comprises a chimeric fusion protein including an extracellular antigen recognition domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the intracellular signal transduction domain includes a functional signal transduction domain derived from a stimulating molecule. In another embodiment, the CAR comprises a chimeric fusion protein including an extracellular antigen recognition domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the intracellular signal transduction domain includes a functional signal transduction domain derived from a co-stimulating molecule and a functional signal transduction domain derived from a stimulating molecule. In yet another embodiment, the CAR comprises a chimeric fusion protein including an extracellular antigen recognition domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the intracellular signal transduction domain includes at least two functional signal transduction domains derived from one or more co-stimulating molecules and a functional signal transduction domain derived from a stimulating molecule.

[0253] The CAR of the present invention can be designed to contain a CD28 signaling domain and / or a 4-1BB signaling domain, or in combination with any other desired cytoplasmic domains in the context of the CAR of the present invention. In one embodiment, the cytoplasmic domain of the CAR may further contain the CD3-ζ signaling domain. For example, the cytoplasmic domain of the CAR may include, but is not limited to, CD3-ζ, 4-1BB, and CD28 signaling modules, and combinations thereof. Therefore, the present invention provides CAR T cells and methods for adoptive therapy thereof.

[0254] This disclosure also provides variants of the CARs, nucleic acids, peptides, and proteins described herein, such as functional variants. A “variant” is a peptide or polynucleotide that differs from a reference peptide or reference polynucleotide due to one or more modifications (e.g., substitution, insertion, or deletion). As used herein, the term “functional variant” refers to a CAR, peptide, or protein that has substantial or significant sequence identity or similarity to a parental CAR, peptide, or protein, and that retains the biological activity of the CAR, peptide, or protein that is a variant of it. Functional variants encompass those variants of, for example, the CARs, peptides, or proteins (parental CARs, peptides, or proteins) described herein, which retain the ability to recognize target cells to a degree, the same degree, or greater than that of the parental CAR, peptide, or protein. Regarding the parental CAR, polypeptide, or protein, the functional variant may, for example, have at least about 30%, about 40%, about 50%, about 60%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or higher identity with the amino acid sequence of the parental CAR, polypeptide, or protein.

[0255] The functional variant may, for example, comprise the amino acid sequence of a parent CAR, peptide, or protein having at least one conserved amino acid substitution. In another embodiment, the functional variant may comprise the amino acid sequence of a parent CAR, peptide, or protein having at least one non-conserved amino acid substitution. In this case, the non-conserved amino acid substitution may not interfere with or inhibit the biological activity of the functional variant. The non-conserved amino acid substitution may enhance the biological activity of the functional variant, such that the biological activity of the functional variant is increased compared to the parent CAR, peptide, or protein.

[0256] The amino acid substitutions in the CAR of the present invention can be conservative amino acid substitutions. Conservative amino acid substitutions are known in the art and include substitutions in which one amino acid having specific physical and / or chemical properties is replaced by another amino acid having the same or similar chemical or physical properties. For example, conservative amino acid substitutions can be the substitution of an acidic amino acid with another acidic amino acid (e.g., Asp or Glu), the substitution of an amino acid with a nonpolar side chain with another amino acid with a nonpolar side chain (e.g., Ala, Gly, Val, Ile, Leu, Met, Phe, Pro, Trp, Val, etc.), the substitution of a basic amino acid with another basic amino acid (Lys, Arg, etc.), the substitution of an amino acid with a polar side chain with another amino acid with a polar side chain (Asn, Cys, Gln, Ser, Thr, Tyr, etc.), and so on.

[0257] The CAR, polypeptide, or protein may consist substantially of one or more specified amino acid sequences as described herein, such that other components (e.g., other amino acids) do not substantially alter the biological activity of the functional variant.

[0258] The CARs, peptides, and proteins (including functional moieties and functional variants) of the embodiments disclosed herein can have any length, i.e., can contain any number of amino acids, provided that the CAR, peptide, or protein (or its functional moieties or functional variants) retains its biological activity, such as the ability to specifically bind antigens, detect diseased cells (e.g., cancer cells) in the host, or treat or prevent diseases in the host. For example, the length of the peptide can be from about 50 to about 5000 amino acids, such as about 50, about 70, about 75, about 100, about 125, about 150, about 175, about 200, about 225, about 250, about 275, about 300, about 325, about 350, about 375, about 400, about 425, about 450, about 47 ... The polypeptides of this invention contain 5, approximately 500, approximately 525, approximately 550, approximately 575, approximately 600, approximately 625, approximately 650, approximately 675, approximately 700, approximately 725, approximately 750, approximately 775, approximately 800, approximately 825, approximately 850, approximately 875, approximately 900, approximately 925, approximately 950, approximately 975, approximately 1000, or more amino acids. The polypeptides of this invention also include oligopeptides.

[0259] The CARs, peptides, and proteins (including the functional portions and functional variants of the invention) of embodiments of the present invention may comprise synthetic amino acids that replace one or more naturally occurring amino acids. Such synthetic amino acids are known in the art and include, for example, aminocyclohexanecarboxylic acid, leucine, α-aminodecanoic acid, homoserine, S-acetaminomethylcysteine, trans-3-hydroxyproline and trans-4-hydroxyproline, 4-aminophenylalanine, 4-nitrophenylalanine, α-(2-amino-2-norbornene)carboxylic acid, α,γ-diaminobutyric acid, α,β-diaminopropionic acid, homophenylalanine, 4-chlorophenylalanine, 4-carboxyphenylalanine, β-phenyl Serine, β-hydroxyphenylalanine, phenylglycine, α-naphthylalanine, cyclohexylalanine, cyclohexylglycine, N'-benzyl-N'-methyl-lysine, N',N'-dibenzyl-lysine, 6-hydroxylysine, ornithine, α-aminocyclopentanecarboxylic acid, α-aminocyclohexanecarboxylic acid, α-aminocycloheptanecarboxylic acid, dihydroindole-2-carboxylic acid, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, aminomalonic acid, aminomalonic acid monoamide, and α-tert-butylglycine.

[0260] The CARs, peptides, and proteins (including functional moieties and functional variants) of embodiments of the present invention can undergo post-translational modifications. They can be glycosylated, esterified, N-acylated, amidated, carboxylated, phosphorylated, esterified, via, for example, disulfide cyclization, or converted into acid addition salts. In some embodiments, they are dimerized or polymerized, or conjugated.

[0261] The CARs, peptides, and / or proteins (including their functional moieties and functional variants) of embodiments of the present invention can be obtained by methods known in the art. Suitable methods for de novo synthesis of peptides and proteins are described in references such as: Chan et al., Fmoc Solid Phase Peptide Synthesis, Oxford University Press, Oxford, United Kingdom, 2000; Peptide and Protein Drug Analysis, Reid, R. (ed.), Marcel Dekker, Inc., 2000; and Epitope Mapping, Westwood et al. (ed.), Oxford University Press, Oxford, United Kingdom, 2001. Alternatively, standard recombinant methods can be used to recombinantly generate peptides and proteins using the nucleic acids described herein. See, for example, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 3rd edition, Cold Spring Harbor Press, Cold Spring Harbor, NY 2001; and Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing Associates and John Wiley & Sons, NY, 1994. Additionally, some of the CARs, peptides, and proteins of the present invention (including their functional moieties and functional variants) can be isolated and / or purified from sources such as plants, bacteria, insects, mammals, etc. Methods for isolation and purification are known in the art. Alternatively, the CARs, peptides, and / or proteins described herein (including their functional moieties and functional variants) can be commercially synthesized. In this respect, the CARs, peptides, and proteins can be synthetic, recombinant, isolated, and / or purified.

[0262] Examples of modified nucleotides that can be used to generate recombinant nucleic acids for producing the polypeptides described herein include, but are not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl)uracil, carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, N... 6-Substituted adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, β-D-mannosylquinoline, 5″-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N 6 -Isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, piracetamidine, β-D-galactosylpiracetamidine, inosine, N 6 -Isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, methyl 5-oxyuracil uracil, 3-(3-amino-3-N-2-carboxypropyl)uracil, and 2,6-diaminopurine.

[0263] The nucleic acid may comprise any isolated or purified nucleotide sequence that encodes a CAR, a polypeptide, or a protein, or a functional portion or variant thereof. Alternatively, the nucleotide sequence may comprise a nucleotide sequence degenerate from or a combination of degenerate sequences.

[0264] Some embodiments of the present invention also provide isolated or purified nucleic acids comprising a nucleotide sequence complementary to the nucleotide sequence of any nucleic acid described herein or a nucleotide sequence hybridizing with the nucleotide sequence of any nucleic acid described herein under stringent conditions.

[0265] Nucleotide sequences that hybridize under stringent conditions can hybridize under highly stringent conditions. "Highly stringent conditions" means that the nucleotide sequence specifically hybridizes with the target sequence (the nucleotide sequence of any nucleic acid described herein) in a detectable amount stronger than nonspecific hybridization. Highly stringent conditions include conditions that distinguish polynucleotides with precisely complementary sequences, or polynucleotides containing only a few scattered mismatches, from random sequences containing a small region (e.g., 3 to 12 bases) that happens to match that nucleotide sequence. These small complementary regions are easier to unwind than full-length complementary sequences of 14 to 17 or more bases, and highly stringent hybridization makes them easily distinguishable. Relatively highly stringent conditions would include, for example, low-salt and / or high-temperature conditions, such as those provided by about 0.02 M NaCl to 0.1 M NaCl or equivalents at temperatures of about 50°C to 70°C. Such highly stringent conditions allow for very few (if any) mismatches between the nucleotide sequence and the template or target strand and are particularly suitable for detecting the expression of any CAR described herein. It is generally believed that conditions can be made more stringent by adding an incremental amount of formamide.

[0266] In one embodiment, the nucleic acids of the present invention may be incorporated into a recombinant expression vector. This disclosure provides recombinant expression vectors comprising any nucleic acid of the present invention. As used herein, the term "recombinant expression vector" means a genetically modified oligonucleotide or polynucleotide construct that, when the construct contains a nucleotide sequence encoding mRNA, a protein, a polypeptide, or a peptide, allows the host cell to express the mRNA, protein, polypeptide, or peptide when the vector is contacted with a host cell under conditions sufficient to allow the mRNA, protein, polypeptide, or peptide to be expressed in the cell. The vectors described herein are not naturally occurring as a whole; however, portions of these vectors may be naturally occurring. The recombinant expression vectors may contain any type of nucleotide, including but not limited to DNA and RNA, which may be single-stranded or double-stranded, synthetic or partially derived from natural sources, and may contain natural, non-natural, or modified nucleotides. The recombinant expression vectors may contain naturally occurring or non-naturally occurring internucleotide bonds, or both. Non-naturally occurring or modified nucleotides or internucleotide bonds do not impede transcription or replication of the vector.

[0267] In one embodiment, the recombinant expression vector of the present invention can be any suitable recombinant expression vector and can be used to transform or transfect any suitable host. Suitable vectors include those designed for proliferation and amplification or for expression, or both, such as plasmids and viruses. Vectors can be selected from the group consisting of: pUC series (Fermentas Life Sciences, Glen Burnie, Md.), pBluescript series (Stratagene, LaJolla, Calif.), pET series (Novagen, Madison, Wis.), pGEX series (Pharmacia Biotech, Uppsala, Sweden), and pEX series (Clontech, Palo Alto, Calif.). Phage vectors such as λGT10, λGT11, λEMBL4, λNM1149, and λZapII (Stratagene) can be used. Examples of plant expression vectors include pBI01, pBI01.2, pBI121, pBI101.3, and pBIN19 (Clontech). Examples of animal expression vectors include pEUK-Cl, pMAM, and pMAMneo (Clontech). Recombinant expression vectors can be viral vectors, such as retroviral vectors, like gamma retroviral vectors.

[0268] In one embodiment, the recombinant expression vector of the present invention is prepared using standard recombinant DNA techniques, such as those described in Sambrook et al. (ibid.) and Ausubel et al. (ibid.). Circular or linear expression vector constructs can be prepared to contain a functional replication system in a prokaryotic or eukaryotic host cell. The replication system may be derived from, for example, ColE1, SV40, 2μ plasmid, λ, bovine papillomavirus, etc.

[0269] Recombinant expression vectors may contain regulatory sequences, such as transcription and translation start and stop codons, which are specific to the host type (e.g., bacteria, plants, fungi, or animals) in which the vector will be appropriately introduced, and take into account whether the vector is DNA-based or RNA-based.

[0270] Recombinant expression vectors may contain one or more marker genes that allow selection of transformed or transfected hosts. Marker genes include biocidal resistance (e.g., resistance to antibiotics, heavy metals, etc.), prototrophic complementation in auxotrophic hosts, and so on. Suitable marker genes for said expression vectors include, for example, neomycin / G418 resistance genes, histidine x resistance genes, histidine resistance genes, tetracycline resistance genes, and ampicillin resistance genes.

[0271] The recombinant expression vector may contain a nucleotide sequence operably linked to encoding the CAR, polypeptide, or protein (including its functional portion and functional variants), or a natural or standard promoter operably linked to a nucleotide sequence complementary to or hybridizing with the nucleotide sequence encoding the CAR, polypeptide, or protein. The selection of the promoter (e.g., a strong promoter, a weak promoter, a tissue-specific promoter, an inducible promoter, and a development-specific promoter) is within the skill of a person skilled in the art. Similarly, the combination of the nucleotide sequence with the promoter is also within the skill of a person skilled in the art. The promoter may be a non-viral promoter or a viral promoter, such as a cytomegalovirus (CMV) promoter, an RSV promoter, an SV40 promoter, or a promoter found in the long terminal repeat sequence of a mouse stem cell virus.

[0272] The recombinant expression vector may contain a nucleotide sequence operatively linked to the CAR, polypeptide, or protein (including its functional portion and functional variants), or one or more additional regulatory elements, such as enhancer elements, 5' and 3' UTRs, or terminator sequences, operatively linked to a nucleotide sequence complementary to or hybridized to the nucleotide sequence encoding the CAR, polypeptide, or protein.

[0273] Recombinant expression vectors can be designed for transient expression, stable expression, or both. Furthermore, they can be prepared for constitutive or inducible expression.

[0274] Additionally, recombinant expression vectors can be prepared to include suicide genes. As used herein, the term "suicide gene" refers to a gene that causes cell death in cells expressing the suicide gene. A suicide gene can be a gene that confers sensitivity to a reagent, such as a drug, to cells expressing the gene and causes cell death upon contact with or exposure to the reagent. Suicide genes are known in the art and include, for example, the herpes simplex virus (HSV) thymidine kinase (TK) gene, cytosine deaminase, purine nucleoside phosphorylase, and nitroreductase.

[0275] Included within the scope of this invention are conjugates (e.g., biological conjugates) comprising any of the following: CAR, polypeptide or protein (including any of its functional portions or functional variants), host cell, nucleic acid, recombinant expression vector, host cell population, or antibody or its antigen-binding portion. Generally, conjugates and methods for synthesizing conjugates are known in the art (see, for example, Hudecz, F., Methods Mol. Biol. 298:209-223 (2005) and Kirin et al., norg Chem. 44(15):5405-5415 (2005)).

[0276] One embodiment of the invention also provides an antibody or an antigen-binding portion thereof that binds (e.g., specifically binds) to an epitope of the CAR of the invention.

[0277] The antibody can be any type of immunoglobulin known in the art. Immunoglobulins can be classified into five major classes: IgA, IgD, IgE, IgG, and IgM. IgA and IgG are further classified into isotypes IgA1, IgA2, IgG1, IgG2, IgG3, and IgG4. The antibody light chain of vertebrate species can be designated as one of two types, κ and λ, based on the amino acid sequence of its constant domain. The antibody can be any type or isotype.

[0278] Antibodies include immunoglobulin molecules, specifically including monoclonal antibodies (including mouse monoclonal antibodies, human monoclonal antibodies, humanized monoclonal antibodies, and chimeric monoclonal antibodies), polyclonal antibodies, antigen-binding fragments, bispecific or multispecific antibodies, monomeric antibodies, dimeric antibodies, tetrameric antibodies, or polymeric antibodies, single-chain antibodies, domain antibodies, and any other modified conformation of an immunoglobulin molecule containing an antigen-binding site with desired specificity. Antibodies can be naturally occurring antibodies, such as antibodies isolated and / or purified from mammals (e.g., mice, primates, rats, rabbits, goats, horses, chickens, hamsters, humans, etc.). Alternatively, antibodies can be engineered (e.g., genetically engineered) antibodies.

[0279] Humanized antibodies possess antigen-binding sites derived from non-human species, and their variable region framework is derived from human immunoglobulin sequences. Human antibodies have heavy chain variable regions and light chain variable regions, where both the framework and antigen-binding sites are derived from human-derived sequences.

[0280] Furthermore, the antibody can possess any level of affinity or affinity for the functional portion of the CAR. In some embodiments, the antibody can have a range of affinities (K... D The antibody binds to the CD79b antigen. In one embodiment of the invention, and in some embodiments of each of the numbered embodiments listed below, the antibody binds to the CD79b antigen with high affinity, for example, as determined by surface plasmon resonance or the Kinexa method, with a KD equal to or less than about 10. -7 M, such as, but not limited to, 1-9.9 (or any range or value therein, such as 1, 2, 3, 4, 5, 6, 7, 8, or 9) × 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M, 10 -12 M, 10 -13 M, 10 -14 M, 10 -15 M, or any range or value thereof, as practiced by those skilled in the art. An example affinity is equal to or less than 1 × 10⁻⁶. -8 M. Another example has an affinity equal to or less than 1 × 10⁻⁶. - 9 M.

[0281] Methods for testing the ability of an antibody to bind to any functional part of a CAR are known in the art and include any antibody-antigen binding assay, such as radioimmunoassay (RIA), Western blotting, enzyme-linked immunosorbent assay (ELISA), immunoprecipitation, and competitive inhibition assay.

[0282] Suitable methods for preparing antibodies are known in the art. For example, the standard hybridoma method is described in the following literature: And Milstein, Eur. J. Immunol., 5, 511-519 (1976), Harlow and Lane (eds.), Antibodies: A Laboratory Manual, CSH Press (1988), and CA Janeway et al. (eds.), Immunobiology, 5th edition, Garland Publishing, New York, NY (2001)). Alternatively, other methods such as the EBV hybridoma method (Haskard and Archer, J. Immunol. Methods, 74(2), 361-67 (1984) and Roder et al., Methods Enzymol., 121, 140-67 (1986)) and phage vector expression systems (see, for example, Huse et al., Science, 246, 1275-81 (1989)) are known in the art. In addition, methods for generating antibodies in non-human animals are described, for example, in U.S. Patent Nos. 5,545,806, 5,569,825 and 5,714,352 and U.S. Patent Application Publication No. 2002 / 0197266A1.

[0283] Phage display can also be used to generate antibodies. In this regard, phage libraries encoding antigen-binding variable (V) domains of antibodies can be generated using standard molecular biology techniques and recombinant DNA techniques (see, for example, Sambrook et al., ibid. and Ausubel et al., ibid.)). A phage encoding a variable region with desired specificity is selected for specific binding to a desired antigen (i.e., CD79b), and an antibody containing the selected variable domain, either fully or partially, is reconstructed. The nucleic acid sequence encoding the reconstructed antibody is introduced into a suitable cell line (such as myeloma cells used to generate hybridomas) so that an antibody with monoclonal antibody properties is secreted by that cell (see, for example, Janeway et al., ibid., Huse et al., and U.S. Patent No. 6,265,150).

[0284] Antibodies can be produced by transgenic mice that are transgenic for specific heavy chain immunoglobulin genes and light chain immunoglobulin genes. Such methods are known in the art and are described, for example, in U.S. Patents 5,545,806 and 5,569,825 and in Janeway et al. (ibid.).

[0285] Methods for generating humanized antibodies are known in the art and described, for example, in Janeway et al. (ibid.), U.S. Patents 5,225,539, 5,585,089, and 5,693,761, European Patent 0239400B1, and British Patent 2,188,638. Humanized antibodies can also be generated using antibody surface reconstruction techniques described in U.S. Patent 5,639,641 and Pedersen et al., J. Mol. Biol., 235,959-973 (1994).

[0286] As used herein, antibodies can be multi-chain or single-chain, or complete immunoglobulins, and can be derived from natural or recombinant sources. Antibodies can be tetramers of immunoglobulin molecules.

[0287] In some implementations, the antibody is a bispecific antibody. The VL and / or VH regions of existing antibodies, or VL and VH regions identified de novo as described herein, can be engineered into a bispecific full-length antibody. Such bispecific antibodies can be prepared by modulating CH3 interactions in the antibody Fc to form bispecific antibodies using techniques such as those described in the following patents: U.S. Patent No. 7,695,936; International Patent Publication No. WO04 / 111233; U.S. Patent Publication No. 2010 / 0015133; U.S. Patent Publication No. 2007 / 0287170; International Patent Publication No. WO2008 / 119353; U.S. Patent Publication No. 2009 / 0182127; U.S. Patent Publication No. 2010 / 0286374; U.S. Patent Publication No. 2011 / 0123532; International Patent Publication No. WO2011 / 131746; International Patent Publication No. WO2011 / 143545; or U.S. Patent Publication No. 2012 / 0149876. For example, the bispecific antibody of the present invention can be generated in vitro in a cell-free environment as follows: according to the method described in International Patent Publication No. WO2011 / 131746, an asymmetric mutation is introduced into the CH3 region of two monospecific homodimers, and a bispecific heterodimer is formed from the two parental monospecific homodimers under reducing conditions that allow disulfide isomerization. In the method, the first and second monospecific bivalent antibodies are engineered to have certain substitutions at the CH3 domain that promote the stability of the heterodimer; these antibodies are incubated together under reducing conditions sufficient to cause disulfide isomerization of cysteine ​​in the hinge region; thereby generating the bispecific antibody through Fab arm exchange. The incubation conditions can ideally be restored to non-reducing conditions. Examples of reducing agents that can be used include 2-mercaptoethylamine (2-MEA), dithiothreitol (DTT), dithioerythritol (DTE), glutathione, tris(2-carboxyethyl)phosphine (TCEP), L-cysteine, and β-mercaptoethanol, preferably reducing agents selected from the group consisting of 2-mercaptoethylamine, dithiothreitol, and tris(2-carboxyethyl)phosphine. For example, the following conditions can be used: incubation for at least 90 minutes in the presence of at least 25 mM 2-MEA or at least 0.5 mM dithiothreitol, at a pH of 5 to 8 (e.g., pH 7.0 or pH 7.4) and at a temperature of at least 20°C.

[0288] The term "antibody fragment" refers to at least a portion of a complete antibody or a recombinant variant thereof that retains the antigen-binding properties of the full-length parent antibody. It refers, for example, an antigen-binding domain, such as the antigen-determining variable region of a complete antibody, sufficient to confer recognition and binding, for example, the specific binding of an antibody fragment to a target (such as an antigen). "Antigen-binding fragment" refers to a portion of an immunoglobulin molecule. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments, single-chain antibodies (scFv), linear antibodies, single-domain antibodies such as sdAb (VL or VH), the Camelidae VHH domain, and multispecific antibodies formed from antibody fragments.

[0289] The term "scFv" refers to a protein comprising at least one antibody fragment containing a light chain variable region and at least one antibody fragment containing a heavy chain variable region. In some embodiments, the light chain variable region and the heavy chain variable region are sequentially linked via a short, flexible peptide linker and are capable of being expressed as a single-chain polypeptide, wherein the scFv retains the specificity of its derived intact antibody. Unless otherwise specified, as used herein, the scFv may have VL and VH variable regions in either order; for example, the scFv may contain VL-linker-VH or VH-linker-VL relative to the N-terminus and C-terminus of the polypeptide.

[0290] The VH and VL domains identified in this study can be incorporated into the scFv format, and the binding and thermal stability of the resulting scFv to CD79b can be assessed using known methods. Binding can be assessed using instruments known to those skilled in the art, such as the ProteOnXPR36, Biacore 3000, or KinExA, ELISA, or competitive binding assays. Binding can be evaluated using purified scFv or E. coli supernatant containing expressed scFv, or lysed cells. The affinity of the tested scFv for CD79b can vary if measured under different conditions (e.g., isotonicity, pH). Therefore, affinity and other binding parameters (e.g., K) may affect the binding stability of the scFv. D K on and K off Measurements of scFv are typically performed using standardized conditions and standardized buffer solutions. Thermal stability can be evaluated by heating the scFv at high temperatures such as 50°C, 55°C, or 60°C for a period of time, such as 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, or 30 minutes, and measuring the binding of the scFv to CD79b. When the scFv maintains the same binding to CD79b as an unheated scFv sample, it is considered thermally stable.

[0291] The CD79b antigen-binding domain may contain sequences encoding variants that exhibit improved thermostability compared to the parental antibody SN8. Engineered sites that can confer improved thermostability include residues M12, I20, R40, and A79 in VH (residue numbered according to SEQ ID NO:283, SN8_VH) and residues L4, D32, F51, V82, and A87 in VL (residue numbered according to SEQ ID NO:284, SN8_VL).

[0292] In recombinant expression systems, the linker is a peptide linker and can contain any naturally occurring amino acid. Exemplary amino acids that can be included in the linker are Gly, Ser, Pro, Thr, Glu, Lys, Arg, Ile, Leu, His, and The. The linker should be long enough to allow VH and VL to connect in the correct conformation relative to each other, thus maintaining their desired activity (such as binding to CD79b).

[0293] The linker length can be approximately 5 to 50 amino acids. In some embodiments, the linker length is approximately 10 to 40 amino acids. In some embodiments, the linker length is approximately 10 to 35 amino acids. In some embodiments, the linker length is approximately 10 to 30 amino acids. In some embodiments, the linker length is approximately 10 to 25 amino acids. In some embodiments, the linker length is approximately 10 to 20 amino acids. In some embodiments, the linker length is approximately 15 to 20 amino acids. In some embodiments, the linker length is 6 amino acids. In some embodiments, the linker length is 7 amino acids. In some embodiments, the linker length is 8 amino acids. In some embodiments, the linker length is 9 amino acids. In some embodiments, the linker length is 10 amino acids. In some embodiments, the linker length is 11 amino acids. In some embodiments, the linker length is 12 amino acids. In some embodiments, the linker length is 13 amino acids. In some embodiments, the linker length is 14 amino acids. In some embodiments, the linker length is 15 amino acids. In some embodiments, the linker length is 16 amino acids. In some embodiments, the linker is 17 amino acids long. In some embodiments, the linker is 18 amino acids long. In some embodiments, the linker is 19 amino acids long. In some embodiments, the linker is 20 amino acids long. In some embodiments, the linker is 21 amino acids long. In some embodiments, the linker is 22 amino acids long. In some embodiments, the linker is 23 amino acids long. In some embodiments, the linker is 24 amino acids long. In some embodiments, the linker is 25 amino acids long. In some embodiments, the linker is 26 amino acids long. In some embodiments, the linker is 27 amino acids long. In some embodiments, the linker is 28 amino acids long. In some embodiments, the linker is 29 amino acids long. In some embodiments, the linker is 30 amino acids long. In some embodiments, the linker is 31 amino acids long. In some embodiments, the linker is 32 amino acids long. In some embodiments, the linker is 33 amino acids long. In some embodiments, the linker is 34 amino acids long. In some embodiments, the linker is 35 amino acids long. In some embodiments, the linker is 36 amino acids long. In some embodiments, the linker is 37 amino acids long. In some embodiments, the linker is 38 amino acids long. In some embodiments, the linker is 39 amino acids long. In some embodiments, the linker is 40 amino acids long.Exemplary connectors that can be used include Gly-rich connectors, connectors containing Gly and Ser, connectors containing Gly and Ala, connectors containing Ala and Ser, and other flexible connectors.

[0294] Other adapter sequences may include portions of the immunoglobulin hinge region, CL, or CH1 derived from any immunoglobulin heavy or light chain isotype. Exemplary adapters that may be used are shown in Table 1. Additional adapters are described, for example, in International Patent Publication No. WO2019 / 060695.

[0295] In some implementations, the scFv includes VH, connector, and VL from the N-terminus to the C-terminus (VH-connector-VL).

[0296] In some implementations, the scFv includes VL, connector, and VH (VL-connector-VH) from the N-end to the C-end.

[0297] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:42.

[0298] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:43.

[0299] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:44.

[0300] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:45.

[0301] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:46.

[0302] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:47.

[0303] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:48.

[0304] In some implementations, the adapter contains the amino acid sequence of SEQ ID NO:49.

[0305] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:50.

[0306] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:51.

[0307] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:52.

[0308] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:53.

[0309] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:54.

[0310] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:55.

[0311] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:56.

[0312] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:57.

[0313] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:58.

[0314] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:59.

[0315] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:60.

[0316] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:61.

[0317] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:62.

[0318] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:63.

[0319] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:64.

[0320] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:65.

[0321] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:66.

[0322] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:67.

[0323] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:68.

[0324] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:69.

[0325] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:70.

[0326] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:71.

[0327] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:72.

[0328] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:73.

[0329] In some embodiments, the adapter contains the amino acid sequence of SEQ ID NO:74.

[0330] Table 1.

[0331]

[0332] One embodiment of the invention also provides an antigen-binding portion of any of the antibodies described herein. This antigen-binding portion can be any portion having at least one antigen-binding site, such as Fab, F(ab')2, dsFv, sFv, biantibodies, and triantibodies.

[0333] In some embodiments, the antigen-binding fragment is a heavy chain complementarity-determining region (HCDR) 1, 2, and / or 3, a light chain complementarity-determining region (LCDR) 1, 2, and / or 3, a heavy chain variable region (VH) or a light chain variable region (VL), a Fab, F(ab')2, Fd, and Fv fragment, and a domain antibody (dAb) comprising (e.g., any of the following) a VH domain or a VL domain. The VH and VL domains may be linked together via a linker (e.g., a synthetic linker).

[0334] The complementarity-determining region (CDR) is the antigen-binding site in an antibody. CDRs can be defined using various terms: (i) a complementarity-determining region (CDR) with three regions in the VH (HCDR1, HCDR2, HCDR3) and three regions in the VL (LCDR1, LCDR2, LCDR3) based on sequence variability (Wu and Kabat, J Exp Med 132:211-50, 1970; Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition Public Health Service, National Institutes of Health, Bethesda, Md., 1991). (ii) The “hypervariant region,” “HVR,” or “HV” refers to a structurally hypervariable region of the antibody variable domain, as defined by Chothia and Lesk (Chothia and Lesk, Mol Biol 196:901-17, 1987). The International Immunogenetics (IMGT) database (http: / / imgt_org) provides standardized numbers and definitions for antigen-binding sites. The correspondence between CDR, HV, and IMGT descriptions is described in Lefranc et al., Dev Comparat Immunol 27:55-77, 2003. Unless otherwise expressly stated, the terms “CDR,” “HCDR1,” “HCDR2,” “HCDR3,” “LCDR1,” “LCDR2,” and “LCDR3” as used herein include the CDR as defined by any of the above methods (Kabat, Chothia, or IMGT).

[0335] In addition, antibodies or their antigen-binding portions can be modified to include detectable tags, such as radioisotopes, fluorophores (e.g., fluorescein isothiocyanate (FITC), phycoerythrin (PE)), enzymes (e.g., alkaline phosphatase, horseradish peroxidase), and elemental particles (e.g., gold particles).

[0336] Exemplary detectable tags include radioactive isotopes, magnetic beads, metal beads, colloidal particles, fluorescent dyes, high-density electron reagents, enzymes (e.g., commonly used in ELISA), biotin, digoxigenin, haptens, luminescent molecules, chemiluminescent molecules, fluorescent dyes, fluorophores, fluorescence quenchers, colored molecules, radioactive isotopes, scintillators, avidin, streptavidin, protein A, protein G, antibodies or fragments thereof, polyhistidine, Ni2+, Flag tags, myc tags, heavy metals, enzymes, alkaline phosphatase, peroxidase, luciferase, electron donors / acceptors, acridinium esters, and colorimetric substrates.

[0337] Detectable tags can spontaneously emit signals, for example, when the detectable tag is a radioactive isotope. In other cases, the detectable tag emits a signal due to stimulation by an external field. Suitable dyes include any commercially available dyes, such as, for example, 5(6)-carboxyfluorescein, IRDye 680RD maleimide or IRDye 800CW, ruthenium polypyridine dyes, etc. Suitable fluorophores are fluorescein isothiocyanate (FITC), thiourea fluorescein, rhodamine, Texas red, CyDyes (e.g., Cy3, Cy5, Cy5.5), Alexa Fluors (e.g., Alexa488, Alexa555, Alexa594; Alexa647), near-infrared (NIR) (700-900 nm) fluorescent dyes, and carbocyanine and aminostyrene dyes.

[0338] This disclosure also provides nucleic acids comprising nucleotide sequences encoding any of the CARs, peptides, or proteins (including their functional portions and functional variants) described herein.

[0339] The portion of the CAR containing an antibody or an antibody fragment thereof can exist in various forms, wherein the antigen-binding domain is represented as part of a continuous polypeptide chain, including, for example, single-domain antibody fragments (sdAbs), scFvs, and human chimeric or humanized antibodies (Harlow et al., 1999, in: Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, in: Antibodies: A Laboratory Manual, Cold Spring Harbor, NY; Ashkenazi et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426). In one aspect, the antigen-binding domain of the CAR composition of the present invention comprises an antibody fragment. In another aspect, the CAR comprises an antibody fragment having an scFv.

[0340] The term "recombinant antibody" refers to antibodies produced using recombinant DNA technology, such as antibodies expressed by phage or yeast expression systems. This term should also be understood to mean antibodies produced by synthesizing a DNA molecule encoding the antibody and expressing the antibody protein, or specifying the amino acid sequence of the antibody, wherein the DNA or amino acid sequence has been obtained using recombinant DNA or amino acid sequencing technologies available and known in the art.

[0341] The term "antigen" refers to a molecule that elicits an immune response. This immune response may involve antibody production, or activation of specific immune-active cells, or both. Those skilled in the art will understand that any macromolecule (including virtually all proteins or peptides) can be used as an antigen. Furthermore, antigens can be derived from recombinant DNA or genomic DNA. Those skilled in the art will understand that any DNA containing a nucleotide sequence or a portion of a protein encoding an immune response therefore encodes the term "antigen" as used herein. Furthermore, those skilled in the art will understand that an antigen need not be encoded solely by the full-length nucleotide sequence of a gene. It will be apparent that this disclosure includes, but is not limited to, the use of partial nucleotide sequences of more than one gene, and that these nucleotide sequences are arranged in various combinations to encode polypeptides that elicit the desired immune response.

[0342] In one aspect, this disclosure provides a CAR comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain binds to the CD79b antigen.

[0343] In one aspect, this disclosure provides a CAR comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises:

[0344] In one embodiment, the extracellular antigen-binding domain includes:

[0345] a) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:1 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:19;

[0346] b) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:1 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:20;

[0347] c) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:2 and light chain complementarity determination regions (CDR)2, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:19;

[0348] d) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:2 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:20;

[0349] e) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:3 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:20;

[0350] f) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:4 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:19;

[0351] g) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:5 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:22;

[0352] h) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:5 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:23;

[0353] i) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:6 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:24;

[0354] j) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:7 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:26;

[0355] k) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:8 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:25;

[0356] l) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:9 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:27;

[0357] m) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:10 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:28;

[0358] n) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:11 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:29;

[0359] o) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:12 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:30;

[0360] p) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:13 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:31;

[0361] q) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:14 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:32;

[0362] r) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:15 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:33;

[0363] s) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:16 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:34;

[0364] t) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:16 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:35;

[0365] u) Heavy chain CDR1, CDR2, and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:17 and light chain CDR1, CDR2, and CDR3 of the light chain variable region (VL) of SEQ ID NO:33; or

[0366] v) Heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:18 and light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:36.

[0367] In one embodiment, the extracellular antigen-binding domain includes:

[0368] The heavy chain CDR1, CDR2 and CDR3 of the heavy chain variable region (VH) of SEQ ID NO:14 and the light chain CDR1, CDR2 and CDR3 of the light chain variable region (VL) of SEQ ID NO:32.

[0369] In one aspect, this disclosure provides a CAR comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises:

[0370] Heavy chain CDR1 having an amino acid sequence selected from the group consisting of SEQ ID NO:208,216,222,228,232,238,242,248,253,257,263,268 and 274 and their conserved modifications, wherein the extracellular antigen-binding domain binds to the CD79b antigen.

[0371] In one aspect, this disclosure provides a CAR comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises:

[0372] Heavy chain CDR2, having an amino acid sequence selected from the group consisting of SEQ ID NO:209, 217, 223, 233, 239, 243, 249, 254, 258, 269 and 275 and their conserved modifications, wherein the extracellular antigen-binding domain binds to the CD79b antigen.

[0373] In one aspect, this disclosure provides a CAR comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises:

[0374] Heavy chain CDR3 having an amino acid sequence selected from the group consisting of SEQ ID NO:210, 218, 224, 229, 234, 240, 244, 250, 255, 259, 264, 270 and 276 and their conserved modifications, wherein the extracellular antigen-binding domain binds to the CD79b antigen.

[0375] In one aspect, this disclosure provides a CAR comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises:

[0376] The heavy chain complementarity-determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:208, the heavy chain CDR2 having the amino acid sequence of SEQ ID NO:209, and the heavy chain CDR3 having the amino acid sequence of SEQ ID NO:210.

[0377] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:216, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:217, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:218;

[0378] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:222, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:223, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:224;

[0379] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:228, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:217, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:229;

[0380] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:232, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:233, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:234;

[0381] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:238, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:239, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:240;

[0382] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:242, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:243, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:244;

[0383] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:248, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:249, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:250;

[0384] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:253, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:254, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:255;

[0385] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:257, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:258, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:259;

[0386] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:263, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:243, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:264;

[0387] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:268, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:269, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:270; or

[0388] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:274, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:275, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:276;

[0389] The extracellular antigen-binding domain thereunder binds to the CD79b antigen.

[0390] In one embodiment, the CAR of this disclosure includes an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain includes:

[0391] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:257, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:258, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:259.

[0392] In one aspect, this disclosure provides a CAR comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises:

[0393] The light chain CDR1 has an amino acid sequence selected from the group consisting of SEQ ID NO:211,214,215,219,225,230,235,241,245,251,260,265,271 and277 and their conserved modifications, wherein the extracellular antigen-binding domain binds to the CD79b antigen.

[0394] In one aspect, this disclosure provides a CAR comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises:

[0395] The light chain CDR2 has an amino acid sequence selected from the group consisting of SEQ ID NO:212,220,226,231,236,246,261,266 and 272 and their conserved modifications, wherein the extracellular antigen-binding domain binds to the CD79b antigen.

[0396] In one aspect, this disclosure provides a CAR comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises:

[0397] The light chain CDR3 has an amino acid sequence selected from the group consisting of SEQ ID NO:213,221,227,237,247,252,256,262,267,273 or 278 and their conserved modifications, wherein the extracellular antigen-binding domain binds to the CD79b antigen.

[0398] In one aspect, this disclosure provides a CAR comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises:

[0399] Light chain CDR1 having the amino acid sequence of SEQ ID NO:211, light chain CDR2 having the amino acid sequence of SEQ ID NO:212, and light chain CDR3 having the amino acid sequence of SEQ ID NO:213;

[0400] Light chain CDR1 having the amino acid sequence of SEQ ID NO:214, light chain CDR2 having the amino acid sequence of SEQ ID NO:212, and light chain CDR3 having the amino acid sequence of SEQ ID NO:213;

[0401] Light chain CDR1 having the amino acid sequence of SEQ ID NO:215, light chain CDR2 having the amino acid sequence of SEQ ID NO:212, and light chain CDR3 having the amino acid sequence of SEQ ID NO:213;

[0402] Light chain CDR1 having the amino acid sequence of SEQ ID NO:219, light chain CDR2 having the amino acid sequence of SEQ ID NO:220, and light chain CDR3 having the amino acid sequence of SEQ ID NO:221;

[0403] Light chain CDR1 having the amino acid sequence of SEQ ID NO:225, light chain CDR2 having the amino acid sequence of SEQ ID NO:226, and light chain CDR3 having the amino acid sequence of SEQ ID NO:227;

[0404] Light chain CDR1 having the amino acid sequence of SEQ ID NO:230, light chain CDR2 having the amino acid sequence of SEQ ID NO:231, and light chain CDR3 having the amino acid sequence of SEQ ID NO:221;

[0405] Light chain CDR1 having the amino acid sequence of SEQ ID NO:235, light chain CDR2 having the amino acid sequence of SEQ ID NO:236, and light chain CDR3 having the amino acid sequence of SEQ ID NO:237;

[0406] Light chain CDR1 having the amino acid sequence of SEQ ID NO:241, light chain CDR2 having the amino acid sequence of SEQ ID NO:226, and light chain CDR3 having the amino acid sequence of SEQ ID NO:227;

[0407] Light chain CDR1 having the amino acid sequence of SEQ ID NO:245, light chain CDR2 having the amino acid sequence of SEQ ID NO:246, and light chain CDR3 having the amino acid sequence of SEQ ID NO:247;

[0408] Light chain CDR1 having the amino acid sequence of SEQ ID NO:251, light chain CDR2 having the amino acid sequence of SEQ ID NO:236, and light chain CDR3 having the amino acid sequence of SEQ ID NO:252;

[0409] Light chain CDR1 having the amino acid sequence of SEQ ID NO:251, light chain CDR2 having the amino acid sequence of SEQ ID NO:236, and light chain CDR3 having the amino acid sequence of SEQ ID NO:256;

[0410] Light chain CDR1 having the amino acid sequence of SEQ ID NO:260, light chain CDR2 having the amino acid sequence of SEQ ID NO:261, and light chain CDR3 having the amino acid sequence of SEQ ID NO:262;

[0411] Light chain CDR1 having the amino acid sequence of SEQ ID NO:265, light chain CDR2 having the amino acid sequence of SEQ ID NO:266, and light chain CDR3 having the amino acid sequence of SEQ ID NO:267;

[0412] Light chain CDR1 having the amino acid sequence of SEQ ID NO:271, light chain CDR2 having the amino acid sequence of SEQ ID NO:272, and light chain CDR3 having the amino acid sequence of SEQ ID NO:273; or

[0413] Light chain CDR1 having the amino acid sequence of SEQ ID NO:277, light chain CDR2 having the amino acid sequence of SEQ ID NO:266, and light chain CDR3 having the amino acid sequence of SEQ ID NO:278;

[0414] The extracellular antigen-binding domain thereunder binds to the CD79b antigen.

[0415] In one embodiment, the CAR of this disclosure includes an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain includes:

[0416] Light chain CDR1 having the amino acid sequence of SEQ ID NO:260, light chain CDR2 having the amino acid sequence of SEQ ID NO:261, and light chain CDR3 having the amino acid sequence of SEQ ID NO:262.

[0417] In one embodiment, the extracellular antigen-binding domain comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2, and the light chain CDR3 having the following amino acid sequence:

[0418] a) These are SEQ ID NO: 208, 209, 210, 211, 212, and 213, respectively;

[0419] b) are SEQ ID NO: 208, 209, 210, 214, 212 and 213 respectively;

[0420] c) are SEQ ID NO: 208, 209, 210, 215, 212 and 213 respectively;

[0421] d) are SEQ ID NO: 216, 217, 218, 219, 220 and 221 respectively;

[0422] e) are SEQ ID NO: 222, 223, 224, 225, 226 and 227 respectively;

[0423] f) are SEQ ID NO: 228, 217, 229, 230, 231 and 221 respectively;

[0424] g) are SEQ ID NO: 232, 233, 234, 235, 236 and 237 respectively;

[0425] h) are SEQ ID NO: 238, 239, 240, 241, 226 and 227 respectively;

[0426] i) are SEQ ID NO:242,243,244,245,246 and 247 respectively;

[0427] j) are SEQ ID NO: 248, 249, 250, 251, 236 and 252 respectively;

[0428] k) are SEQ ID NO: 253, 254, 255, 251, 236 and 256 respectively;

[0429] l) are SEQ ID NO:257,258,259,260,261 and262 respectively;

[0430] m) are SEQ ID NO:263,243,264,265,266 and 267 respectively;

[0431] n) are SEQ ID NO: 268, 269, 270, 271, 272 and 273 respectively; or

[0432] o) are SEQ ID NO:274,275,276,277,266 and 278 respectively.

[0433] In one embodiment, the extracellular antigen-binding domain comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2, and the light chain CDR3 having the following amino acid sequences: SEQ ID NO: 257, 258, 259, 260, 261, and 262, respectively.

[0434] In one embodiment, the extracellular antigen-binding domain includes

[0435] The heavy chain variable domain (HCVH) comprising an amino acid sequence selected from SEQ ID NO:1-18; the light chain variable domain (LCVL) comprising an amino acid sequence selected from SEQ ID NO:19-36; or a combination of an HCVH comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18 and an LCVL comprising an amino acid sequence selected from the group consisting of SEQ ID NO:19-36.

[0436] In one embodiment, the extracellular antigen-binding domain includes:

[0437] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:1 and the light chain variable region containing the amino acid sequence of SEQ ID NO:19;

[0438] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:1 and the light chain variable region containing the amino acid sequence of SEQ ID NO:20;

[0439] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:2 and the light chain variable region containing the amino acid sequence of SEQ ID NO:19;

[0440] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:2 and the light chain variable region containing the amino acid sequence of SEQ ID NO:20;

[0441] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:3 and the light chain variable region containing the amino acid sequence of SEQ ID NO:20;

[0442] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:4 and the light chain variable region containing the amino acid sequence of SEQ ID NO:19;

[0443] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:5 and the light chain variable region containing the amino acid sequence of SEQ ID NO:22;

[0444] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:5 and the light chain variable region containing the amino acid sequence of SEQ ID NO:23;

[0445] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:6 and the light chain variable region containing the amino acid sequence of SEQ ID NO:24;

[0446] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:7 and the light chain variable region containing the amino acid sequence of SEQ ID NO:26;

[0447] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:8 and the light chain variable region containing the amino acid sequence of SEQ ID NO:25;

[0448] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:9 and the light chain variable region containing the amino acid sequence of SEQ ID NO:27;

[0449] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:10 and the light chain variable region containing the amino acid sequence of SEQ ID NO:28;

[0450] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:11 and the light chain variable region containing the amino acid sequence of SEQ ID NO:29;

[0451] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:12 and the light chain variable region containing the amino acid sequence of SEQ ID NO:30;

[0452] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:13 and the light chain variable region containing the amino acid sequence of SEQ ID NO:31;

[0453] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:14 and the light chain variable region containing the amino acid sequence of SEQ ID NO:32;

[0454] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:15 and the light chain variable region containing the amino acid sequence of SEQ ID NO:33;

[0455] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:16 and the light chain variable region containing the amino acid sequence of SEQ ID NO:34;

[0456] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:16 and the light chain variable region containing the amino acid sequence of SEQ ID NO:35;

[0457] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:17 and the light chain variable region containing the amino acid sequence of SEQ ID NO:33; or

[0458] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:18 and the light chain variable region containing the amino acid sequence of SEQ ID NO:36.

[0459] In one embodiment, the extracellular antigen-binding domain includes:

[0460] The heavy chain variable region containing the amino acid sequence of SEQ ID NO:14 and the light chain variable region containing the amino acid sequence of SEQ ID NO:32.

[0461] In one embodiment, the extracellular antigen-binding domain includes:

[0462] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:1; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:19;

[0463] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:1; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:20;

[0464] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:2; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:19;

[0465] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:2; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:20;

[0466] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:3; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:20;

[0467] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:4; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:19;

[0468] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:5; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:22;

[0469] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:5; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:23;

[0470] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:6; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:24;

[0471] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:7; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:26;

[0472] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:8; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:25;

[0473] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:9; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:27;

[0474] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:10; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:28;

[0475] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:11; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:29;

[0476] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:12; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:30;

[0477] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:13; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:31;

[0478] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:14; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:32;

[0479] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:15; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:33;

[0480] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:16; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:34;

[0481] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:16; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:35;

[0482] The heavy chain variable region comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:17; and the light chain variable region comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:33; or

[0483] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:18; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:36.

[0484] In one embodiment, the extracellular antigen-binding domain includes:

[0485] The heavy chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:14; and the light chain variable region comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:32.

[0486] In one embodiment, the extracellular antigen-binding domain comprises an scFv. In some embodiments, the scFv comprises a linker polypeptide located between the light chain variable region and the heavy chain variable region. In some embodiments, the extracellular antigen-binding domain is an scFv comprising an amino acid sequence selected from the group consisting of SEQ ID NO:75-118 and associated with a CD79b polypeptide (e.g., a human CD79b polypeptide having the amino acid sequence described herein or a fragment thereof). In some embodiments, the linker polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:42-74.

[0487] In one embodiment, the adapter polypeptide comprises the amino acid sequence of SEQ ID NO:42. In another embodiment, the adapter polypeptide comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:42.

[0488] In one embodiment, the scFv comprises an amino acid sequence selected from the group consisting of SEQ ID NO:75-118. In one embodiment, the scFv comprises the amino acid sequence of SEQ ID NO:75. In one embodiment, the scFv comprises the amino acid sequence of SEQ ID NO:76. In one embodiment, the scFv comprises the amino acid sequence of SEQ ID NO:77. In one embodiment, the scFv comprises the amino acid sequence of SEQ ID NO:78. In one embodiment, the scFv comprises the amino acid sequence of SEQ ID NO:79. In one embodiment, the scFv comprises the amino acid sequence of SEQ ID NO:80. In one embodiment, the scFv comprises the amino acid sequence of SEQ ID NO:81. In one embodiment, the scFv comprises the amino acid sequence of SEQ ID NO:82. In one embodiment, the scFv comprises the amino acid sequence of SEQ ID NO:83. In one embodiment, the scFv comprises the amino acid sequence of SEQ ID NO:84. In one embodiment, the scFv comprises the amino acid sequence of SEQ ID NO:85. In one embodiment, the scFv comprises the amino acid sequence of SEQ ID NO:86. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:87. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:88. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:89. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:90. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:91. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:92. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:93. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:94. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:95. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:96. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:97. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:98. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:99. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:100. In another embodiment, the scFv contains the amino acid sequence of SEQ ID NO:101.In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:102. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:103. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:104. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:105. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:106. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:107. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:108. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:109. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:110. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:111. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:112. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:113. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:114. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:115. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:116. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:117. In one embodiment, the scFv contains the amino acid sequence of SEQ ID NO:118.

[0489] In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with a sequence selected from the group consisting of SEQ ID NO:75. In another embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:75. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:76. In another embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:77. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:78. In another embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:79. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:80.In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:81. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:82. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:83. In another embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:84. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:85. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:86. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:87.In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:88. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:89. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:90. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:91. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:93. In another embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:93. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:94.In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:95. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:96. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:97. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:98. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:99. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:100. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:101.In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:102. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:103. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:104. In another embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:105. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:106. In another embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:107. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:108.In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:109. In another embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:110. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:111. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:112. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:113. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:114. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:115.In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:116. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:117. In one embodiment, the scFv comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:118.

[0490] In one embodiment, the extracellular antigen-binding domain is an scFv comprising the amino acid sequence of SEQ ID NO:113, or an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:113.

[0491] In one embodiment, the extracellular antigen-binding domain comprises a signaling polypeptide. In some embodiments, the signaling polypeptide comprises the amino acid sequence of SEQ ID NO:37. In one embodiment, the signaling polypeptide comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:37.

[0492] In one aspect, this disclosure provides a CAR comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:119-162. Another feature of a CAR having an extracellular antigen-binding domain comprising an amino acid sequence selected from SEQ ID NO:119-162 is that the extracellular antigen-binding domain binds to the CD79b antigen.

[0493] In one embodiment, the intracellular signal transduction domain comprises a polypeptide component selected from the group consisting of: TNF receptor superfamily member 9 (CD137) component, T cell surface glycoprotein CD3ζ chain (CD3z) component, differentiation cluster (CD27) component, differentiation cluster superfamily member (such as CD28 or inducible T cell costimulator (ICOS)) component, and combinations thereof.

[0494] In one embodiment, the CD137 component comprises the amino acid sequence of SEQ ID NO:40. In another embodiment, the CD137 component comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:40.

[0495] In one embodiment, the CD3z component comprises the amino acid sequence of SEQ ID NO:41. In another embodiment, the CD3z component comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:41.

[0496] In one embodiment, the intracellular signal transduction domain comprises the amino acid sequence of SEQ ID NO:163. In another embodiment, the intracellular signal transduction domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:163.

[0497] In one embodiment, the transmembrane domain comprises a CD8a transmembrane region (CD8a-TM) polypeptide. In some embodiments, the CD8a-TM polypeptide comprises the amino acid sequence of SEQ ID NO:39. In some embodiments, the CD8a-TM polypeptide comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:39.

[0498] In one embodiment, the transmembrane domain comprises at least a transmembrane region of the following: the α, β, or ζ chain of a T-cell receptor; CD28, CD3ε, CD45, CD4, CD5, CD8, CD8α, CD9, CD16, CD22, CD33, CD37, CD40, CD64, CD80, CD86, CD134, CD137, or CD154. In another embodiment, the transmembrane domain comprises at least a transmembrane domain having the following: ζ, η, or FcεR1γ and -β, MB1 (Igα.), B29 or CD3-γ, ζ, or η. In yet another embodiment, the transmembrane domain is synthetic, for example, primarily comprising hydrophobic residues such as leucine and valine, a phenylalanine triplet, or tryptophan.

[0499] In one embodiment, the CAR further includes a hinge region linking the transmembrane domain to the extracellular antigen-binding domain. In some embodiments, the hinge region is a CD8a hinge region. In some embodiments, the CD8a hinge region contains the amino acid sequence of SEQ ID NO:38. In some embodiments, the CD8a hinge region contains an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:38. In some embodiments, the hinge region comprises the sequence EPKSCDKTHTCPPCP (SEQ ID NO:285), or comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with EPKSCDKTHTCPPCP (SEQ ID NO:285). In some embodiments, the hinge region comprises the sequence ERKCCVECPPCP (SEQ ID NO:286), or comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with ERKCCVECPPCP (SEQ ID NO:286). In some embodiments, the hinge region comprises the sequence ELKTPLGDTTHTCPRCP(EPKSCDTPPPCPRCP)3 (SEQ ID NO:287), or comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with ELKTPLGDTTHTCPRCP(EPKSCDTPPPCPRCP)3 (SEQ ID NO:287). In some embodiments, the hinge region comprises the sequence ESKYGPPCPSCP (SEQ ID NO:288), or comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with ESKYGPPCPSCP (SEQ ID NO:288).

[0500] In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:119-162. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:119. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:120. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:121. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:122. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:123. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:124. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:125. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:126. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:127. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO: 128. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO: 129. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO: 130. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO: 131. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO: 132. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO: 133. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO: 134. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO: 135. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO: 136. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO: 137. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO: 138. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:139. In another embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:140.In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:141. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:142. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:143. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:144. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:145. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:146. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:147. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:148. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:149. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:150. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:151. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:152. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:153. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:154. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:155. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:156. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:157. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:158. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:159. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:160. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:161. In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:162.

[0501] In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with a sequence selected from the group consisting of SEQ ID NO:119. In another embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:119. In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:120. In another embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:121. In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:122. In another embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:123. In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:124.In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:125. In another embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:126. In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:127. In another embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:128. In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:129. In another embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:130. In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:131.In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:132. In another embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:133. In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:134. In another embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:135. In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:136. In another embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:137. In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:138.In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:139. In another embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:140. In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:141. In another embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:142. In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:143. In another embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:144. In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:145.In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:146. In another embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:147. In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:148. In another embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:149. In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:150. In another embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:151. In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:152.In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:153. In another embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:154. In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:155. In another embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:156. In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:157. In another embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:158. In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:159.In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:160. In another embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:161. In one embodiment, the extracellular antigen-binding domain comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:162.

[0502] In one embodiment, the extracellular antigen-binding domain comprises the amino acid sequence of SEQ ID NO:157, or an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:157.

[0503] CAR constructs and CAR-expressing immune response cells

[0504] In one embodiment, this disclosure provides a cell expressing a nucleic acid molecule encoding a CAR. In one embodiment, the CAR of this disclosure comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:164-207. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:164, or comprises the sequence of SEQ ID NO:164. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:165, or comprises the sequence of SEQ ID NO:165. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:166, or comprises the sequence of SEQ ID NO:166. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:167, or comprises the sequence of SEQ ID NO:167. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:168, or comprises the sequence of SEQ ID NO:168. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:169, or a sequence comprising SEQ ID NO:169.In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:170, or comprises the sequence of SEQ ID NO:170. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:171, or comprises the sequence of SEQ ID NO:171. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:172, or comprises the sequence of SEQ ID NO:172. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:173, or comprises the sequence of SEQ ID NO:173. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:174, or comprises the sequence of SEQ ID NO:174. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:175, or comprises the sequence of SEQ ID NO:175.In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:176, or comprises the sequence of SEQ ID NO:176. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:177, or comprises the sequence of SEQ ID NO:177. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:178, or comprises the sequence of SEQ ID NO:178. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:179, or comprises the sequence of SEQ ID NO:179. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:180, or comprises the sequence of SEQ ID NO:180. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:181, or comprises the sequence of SEQ ID NO:181.In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:182, or comprises the sequence of SEQ ID NO:182. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:183, or comprises the sequence of SEQ ID NO:183. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:184, or comprises the sequence of SEQ ID NO:184. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:185, or comprises the sequence of SEQ ID NO:185. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:186, or comprises the sequence of SEQ ID NO:186. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:187, or comprises the sequence of SEQ ID NO:187.In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:188, or comprises the sequence of SEQ ID NO:188. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:189, or comprises the sequence of SEQ ID NO:189. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:190, or comprises the sequence of SEQ ID NO:190. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:191, or comprises the sequence of SEQ ID NO:191. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:192, or comprises the sequence of SEQ ID NO:192. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:193, or comprises the sequence of SEQ ID NO:193.In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:194, or comprises the sequence of SEQ ID NO:194. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:195, or comprises the sequence of SEQ ID NO:195. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:196, or comprises the sequence of SEQ ID NO:196. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:197, or comprises the sequence of SEQ ID NO:197. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:198, or comprises the sequence of SEQ ID NO:198. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:199, or comprises the sequence of SEQ ID NO:199.In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:200, or comprises the sequence of SEQ ID NO:200. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:201, or comprises the sequence of SEQ ID NO:201. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:202, or comprises the sequence of SEQ ID NO:202. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:203, or comprises the sequence of SEQ ID NO:203. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:204, or comprises the sequence of SEQ ID NO:204. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:205, or comprises the sequence of SEQ ID NO:205.In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:206, or comprises the sequence of SEQ ID NO:206. In some embodiments, the CAR of this disclosure comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:207, or comprises the sequence of SEQ ID NO:207.

[0505] In some embodiments, the CAR of this disclosure comprises the amino acid sequence of SEQ ID NO:202.

[0506] In one aspect, this disclosure provides isolated immune-response cells comprising the CAR described herein. In some embodiments, the isolated immune-response cells are transduced with the CAR, for example, the CAR is constitutively expressed on the surface of the immune-response cells. In some embodiments, the isolated immune-response cells are further transduced with at least one co-stimulatory ligand, such that the immune-response cells express the at least one co-stimulatory ligand. In some embodiments, the at least one co-stimulatory ligand is selected from the group consisting of: 4-1BBL, CD48, CD70, CD80, CD86, OX40L, TNFRSF14, and combinations thereof. In some embodiments, the isolated immune-response cells are further transduced with at least one cytokine, such that the immune-response cells secrete the at least one cytokine. In some embodiments, the at least one cytokine is selected from the group consisting of: IL-2, IL-3, IL-6, IL-7, IL-11, IL-12, IL-15, IL-17, IL-21, and combinations thereof. In some implementations, the isolated immune response cells are selected from the group consisting of: T lymphocytes (T cells), natural killer (NK) cells, cytotoxic T lymphocytes (CTLs), regulatory T cells, human embryonic stem cells, lymphoid progenitor cells, T cell precursor cells, and pluripotent stem cells from which lymphoid cells can differentiate.

[0507] In one embodiment, the CAR T cells of this disclosure can be generated by introducing a lentiviral vector containing a desired CAR (e.g., a CAR containing an anti-CD79b domain, a CD8α hinge and transmembrane domain, and human 4-1BB and CD3ζ signaling domains) into cells. The CAR T cells of this invention are capable of replicating in vivo, thereby leading to long-term persistence that can induce sustained tumor control.

[0508] Embodiments of the present invention also provide host cells comprising any of the recombinant expression vectors described herein. As used herein, the term "host cell" refers to any type of cell that may contain a recombinant expression vector. Host cells may be eukaryotic cells (e.g., plants, animals, algae, fungi) or prokaryotic cells (e.g., bacteria or protozoa). Host cells may be cultured cells or primary cells (i.e., directly isolated from an organism (e.g., humans)). Host cells may be adherent cells or suspension cells, i.e., cells grown in suspension. Suitable host cells are known in the art and include, for example, DH5α *Escherichia coli* (E. coli) cells, Chinese hamster ovary cells, monkey VERO cells, COS cells, HEK293 cells, etc. For amplification or replication of the recombinant expression vector, the host cell may be a prokaryotic cell, such as DH5α cells. For the production of recombinant CARs, peptides, or proteins, the host cell may be a mammalian cell. The host cell may be a human cell. While the host cell may be any cell type, may originate from any type of tissue, and may be at any developmental stage, the host cell may be a peripheral blood lymphocyte (PBL). The host cell can be a T cell.

[0509] For the purposes of this document, T cells can be any type of T cell, such as cultured T cells (e.g., primary T cells), T cells derived from cultured T cell lines (e.g., Jurkat, SupT1, etc.), or T cells obtained from mammals. If obtained from mammals, T cells can be obtained from a variety of sources, including but not limited to bone marrow, blood, lymph nodes, thymus, or other tissues or fluids. T cells may also be enriched or purified. T cells can be human T cells. T cells can be T cells isolated from humans. T cells can be any type of T cell and can be at any developmental stage, including but not limited to CD4. + / CD8 + Double-positive T cells, CD8 + T cells (e.g., cytotoxic T cells), CD4 + Helper T cells (e.g., Th1 and Th2 cells), peripheral blood mononuclear cells (PBMCs), peripheral blood leukocytes (PBLs), tumor-infiltrating cells, memory T cells, naive T cells, etc. T cells can be CD8+. + T cells or CD4+ T cells.

[0510] A cell population comprising at least one host cell described herein is also provided. The cell population can be a heterogeneous population comprising host cells having any of the recombinant expression vectors, and additionally comprising at least one other cell type, such as host cells not having any of the recombinant expression vectors (e.g., T cells), or cells other than T cells, such as B cells, macrophages, erythrocytes, neutrophils, hepatocytes, endothelial cells, epithelial cells, muscle cells, brain cells, etc. Alternatively, the cell population can be a substantially homogeneous population, wherein the population primarily comprises (e.g., is substantially composed of) host cells having the recombinant expression vector. The population can also be a clonal population of cells, wherein all cells in the population are clones of a single host cell containing the recombinant expression vector, such that all cells in the population contain the recombinant expression vector. In one embodiment, the cell population is a clonal population comprising host cells having the recombinant expression vector as described herein.

[0511] Pharmaceutical composition / application

[0512] In embodiments of this disclosure, CAR-expressing cells may be provided in the composition, for example, a suitable pharmaceutical composition comprising CAR-expressing cells and a pharmaceutically acceptable carrier. In one aspect, this disclosure provides a pharmaceutical composition comprising an effective amount of lymphocytes expressing one or more of the said CARs and a pharmaceutically acceptable excipient. The pharmaceutical compositions of this disclosure may comprise a combination of CAR-expressing cells (e.g., multiple CAR-expressing cells as described herein) and one or more pharmaceutically or physiologically acceptable carriers, excipients, or diluents. A pharmaceutically acceptable carrier may be a component of the pharmaceutical composition other than the active ingredient, and is non-toxic to the subject.

[0513] Pharmaceutically acceptable carriers may include, but are not limited to, buffers, excipients, stabilizers, or preservatives. Examples of pharmaceutically acceptable carriers are physiologically compatible solvents, dispersion media, coating agents, antibacterial and antifungal agents, isotonic agents, and absorption delay agents, such as salts, buffers, antioxidants, sugars, aqueous or non-aqueous carriers, preservatives, wetting agents, surfactants, or emulsifiers, or combinations thereof. The amount of a pharmaceutically acceptable carrier in a pharmaceutical composition may be determined experimentally based on carrier activity and desired formulation characteristics (e.g., stability and / or minimal oxidation).

[0514] Such compositions may contain buffers such as acetic acid, citric acid, formic acid, succinic acid, phosphoric acid, carbonic acid, malic acid, aspartic acid, histidine, boric acid, Tris buffer, HEPPSO, HEPES, neutral buffered saline, phosphate buffered saline, etc.; carbohydrates such as glucose, mannose, sucrose or dextran, mannitol; proteins; peptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); antibacterial and antifungal agents; and preservatives.

[0515] The compositions disclosed herein can be formulated for various methods of parenteral or non-parenteral administration. In one embodiment, the compositions can be formulated for infusion or intravenous administration. The compositions disclosed herein can be provided, for example, as sterile liquid formulations (e.g., isotonic aqueous solutions, emulsions, suspensions, dispersions, or viscous compositions) that can be buffered to a desired pH. Formulations suitable for oral administration can include liquid solutions, capsules, pouches, tablets, lozenges and sugar tablets, powders, and liquid suspensions in suitable liquids and emulsions.

[0516] As used in this article with respect to pharmaceutical compositions, the term "pharmaceuticalally acceptable" means a substance approved by a federal or state regulatory agency or listed in the United States Pharmacopeia or other recognized pharmacopoeia for use in animals and / or humans.

[0517] In one aspect, this disclosure relates to the use of lymphocyte infusion to administer genetically modified T cells expressing CAR for the treatment of subjects who have cancer or are at risk of developing cancer. In at least one embodiment, autologous lymphocyte infusion is used in the treatment. Autologous PBMCs are collected from the subject in need of treatment, and the T cells are activated and expanded using methods described herein and known in the art, and then infused back into the subject.

[0518] In one aspect, this disclosure relates throughout to the treatment of subjects at risk of developing cancer. The invention also includes the treatment of malignancies or autoimmune diseases in which chemotherapy and / or immunotherapy in a subject results in significant immunosuppression, thereby increasing the subject's risk of developing cancer. In one aspect, this disclosure provides a method for cancer prevention, the method comprising administering an amount of lymphocytes expressing one or more of the CARs to a subject in need.

[0519] In one aspect, this disclosure provides a method for treating a subject with cancer, the method comprising administering a therapeutically effective amount of lymphocytes expressing one or more of the CARs to the subject in need, whereby the lymphocytes induce or modulate the killing of cancer cells in the subject.

[0520] In another aspect, this disclosure provides a method for reducing tumor burden in subjects with cancer, the method comprising administering a therapeutically effective amount of lymphocytes expressing one or more of the CARs described herein to a subject in need, thereby inducing the killing of cancer cells in the subject. In another aspect, this disclosure provides a method for prolonging the survival of subjects with cancer, the method comprising administering a therapeutically effective amount of lymphocytes expressing one or more of the CARs to a subject in need, thereby prolonging the survival of the subject. Generally, lymphocytes expressing the CAR induce the killing of cancer cells in the subject, resulting in a reduction or eradication of tumor cells / cancer cells in the subject. A non-limiting list of cancers (including targetable metastatic lesions) includes B-cell lymphoma and cancers of B-cell origin. In one embodiment, the cancer treated in the subject is B-cell lymphoma. In some embodiments, the cancer is non-Hodgkin lymphoma. In some implementations, the cancer is a hematopoietic cancer, such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZ), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), mucosa-associated lymphoid tissue (MALT) lymphoma, Hodgkin's lymphoma, Burkitt's lymphoma, hairy cell leukemia, or plasmacytoma.

[0521] In one aspect, a method of treating a subject suffering from cancer is provided, comprising administering to a subject in need a therapeutically effective amount of lymphocytes expressing a CAR (the CAR having an extracellular antigen-binding domain that binds to the CD79b antigen), whereby the lymphocytes induce the killing of cancer cells in the subject. In some embodiments, at least one of the CARs comprises an amino acid sequence selected from the group consisting of SEQ ID NO:164-207. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:164, or comprises the sequence of SEQ ID NO:164. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:165, or comprises the sequence of SEQ ID NO:165. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:166, or comprises the sequence of SEQ ID NO:166. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:167, or comprises the sequence of SEQ ID NO:167. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:168, or comprises the sequence of SEQ ID NO:168.In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:169, or comprises the sequence of SEQ ID NO:169. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:170, or comprises the sequence of SEQ ID NO:170. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:171, or comprises the sequence of SEQ ID NO:171. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:172, or comprises the sequence of SEQ ID NO:172. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:173, or comprises the sequence of SEQ ID NO:173. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:174, or comprises the sequence of SEQ ID NO:174.In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:175, or comprises the sequence of SEQ ID NO:175. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:176, or comprises the sequence of SEQ ID NO:176. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:177, or comprises the sequence of SEQ ID NO:177. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:178, or comprises the sequence of SEQ ID NO:178. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:179, or comprises the sequence of SEQ ID NO:179. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:180, or comprises the sequence of SEQ ID NO:180.In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:181, or comprises the sequence of SEQ ID NO:181. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:182, or comprises the sequence of SEQ ID NO:182. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:183, or comprises the sequence of SEQ ID NO:183. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:184, or comprises the sequence of SEQ ID NO:184. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:185, or comprises the sequence of SEQ ID NO:185. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:186, or comprises the sequence of SEQ ID NO:186.In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:187, or comprises the sequence of SEQ ID NO:187. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:188, or comprises the sequence of SEQ ID NO:188. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:189, or comprises the sequence of SEQ ID NO:189. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:190, or comprises the sequence of SEQ ID NO:190. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:191, or comprises the sequence of SEQ ID NO:191. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:192, or comprises the sequence of SEQ ID NO:192.In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:193, or comprises the sequence of SEQ ID NO:193. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:194, or comprises the sequence of SEQ ID NO:194. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:195, or comprises the sequence of SEQ ID NO:195. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:196, or comprises the sequence of SEQ ID NO:196. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:197, or comprises the sequence of SEQ ID NO:197. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:198, or comprises the sequence of SEQ ID NO:198.In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:199, or comprises the sequence of SEQ ID NO:199. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:200, or comprises the sequence of SEQ ID NO:200. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:201, or comprises the sequence of SEQ ID NO:201. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:202, or comprises the sequence of SEQ ID NO:202. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:203, or comprises the sequence of SEQ ID NO:203. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:204, or comprises the sequence of SEQ ID NO:204.In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:205, or comprises the sequence of SEQ ID NO:205. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO:206, or comprises the sequence of SEQ ID NO:206. In some embodiments, the CAR comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:207, or comprises a sequence of SEQ ID NO:207.

[0522] In one aspect, a method for targeted killing of cancer cells is disclosed, the method comprising contacting cancer cells with lymphocytes expressing one or more of the CARs, thereby inducing the killing of cancer cells by the lymphocytes. A non-limiting list of targetable cancer cells (including metastatic cancer cells) includes B-cell lymphomas, non-Hodgkin lymphomas, and combinations thereof. In one embodiment, the cancer cells are malignant B cells.

[0523] The pharmaceutical compositions disclosed herein can be administered in a manner suitable for treating (or preventing) a disease. The amount and frequency of administration will be determined by factors such as the subject's condition and the type and severity of the subject's disease, but an appropriate dosage can be determined through clinical trials.

[0524] When a therapeutically effective dose is indicated, the precise amount of the composition of this disclosure to be administered can be determined by a physician taking into account individual differences in the subject's age, weight, tumor size, degree of infection or metastasis, and condition. Generally speaking, it can be said that the pharmaceutical composition containing the T cells described herein can be administered in doses of approximately 10... 4 Cells / kg body weight to approximately 10 10 Cells / kg body weight, in some cases approximately 10 5 Cells / kg body weight to approximately 10 6 The dosage is 1 cell / kg body weight (including all integer values ​​within those ranges). In some embodiments, the pharmaceutical composition containing the T cells described herein can be administered at approximately 10 6Administered at a dose of cells per kg body weight. The T-cell composition may also be administered multiple times at these doses. These cells may be administered using infusion techniques commonly known in immunotherapy (see, for example, Rosenberg et al., New Eng. J. of Med. 319:1676, 1988).

[0525] Delivery systems applicable in the context of embodiments of the present invention may include timed-release delivery systems, delayed-release delivery systems, and sustained-release delivery systems, such that the delivery of the T-cell composition occurs before sensitization at the treatment site and allows sufficient time to induce sensitization. The composition may be used in combination with other therapeutic agents or therapies. Such systems can avoid repeated administration of the composition, thereby increasing convenience for subjects and physicians, and may be particularly suitable for certain composition embodiments of the present invention.

[0526] Many types of release and delivery systems are available and are known to those skilled in the art. These release and delivery systems include polymer-based systems such as poly(lactide-glycolic acid), copolyoxalate, polyesteramide, polyorthoester, polycaprolactone, polyhydroxybutyrate, and polyanhydride. Microcapsules containing the aforementioned drug-containing polymers are described, for example, in U.S. Patent 5,075,109. Delivery systems also include non-polymer systems that are lipids, including sterols (such as cholesterol, cholesterol esters, and fatty acids or neutral fats (such as monoglycerides, diglycerides, and triglycerides)); silicone rubber systems; peptide-based systems; hydrogel release systems; wax coatings; tablets using conventional adhesives and excipients; partially molten implants; and so on. Specific examples include, but are not limited to: (a) erosion systems in which the active composition is contained within a matrix in a form such as those described in U.S. Patent Nos. 4,452,775; 4,667,014; 4,748,034; and 5,239,660; and (b) diffusion systems in which the active component permeates from the polymer at a controlled rate such as those described in U.S. Patent Nos. 3,854,480 and 3,832,253. Additionally, pump-based hardware delivery systems may be used, some of which are suitable for implantation.

[0527] In some respects, it may be advantageous to administer activated T cells to the subject, then draw blood again (or perform apheresis), activate the T cells according to this disclosure, and re-infuse these activated and expanded T cells into the subject. This process can be performed multiple times every few weeks. In some respects, T cells from 10 cc to 400 cc of blood can be activated. In some respects, T cells from 20 cc, 30 cc, 40 cc, 50 cc, 60 cc, 70 cc, 80 cc, 90 cc, or 100 cc of blood can be activated.

[0528] CAR-T cells and compositions can be administered in any manner, such as parenteral or non-parenteral administration, including via aerosol inhalation, injection, infusion, uptake, transfusion, implantation, or transplantation. For example, the CAR-T cells and compositions described herein can be administered to patients via artery, intradermal, subcutaneous, intratumoral, intramedullary, intranodal, intramuscular, intravenous (iv), or intraperitoneal injection. In one aspect, the compositions of this disclosure are administered via intravenous injection. In another aspect, the compositions of this disclosure are administered to subjects via intradermal or subcutaneous injection. The T-cell compositions can be injected directly into, for example, tumors, lymph nodes, tissues, organs, or sites of infection.

[0529] Administration can be autologous or non-autologous. For example, immune response cells expressing a differentiation cluster 79B protein (e.g., CD79b)-specific CAR can be obtained from a subject and administered to the same subject or different compatible subjects. Peripheral blood-derived T cells or expanded T cells (e.g., in vivo, ex vivo, or in vitro derived) of this disclosure can be administered via, for example, intravenous injection, local injection, systemic injection, catheter administration, or parenteral administration.

[0530] In certain embodiments, a subject may undergo leukapheresis, in which leukocytes are collected, enriched, or removed in vitro to select and / or isolate cells of interest (e.g., T cells). These T cell isolates may be expanded using methods known in the art and processed to allow the introduction of one or more CAR constructs of this disclosure, thereby forming CAR-T cells. Subsequently, the subject in need may undergo standard treatment with high-dose chemotherapy followed by peripheral blood stem cell transplantation. In some aspects, the subject receives an infusion of expanded CAR-T cells after or concurrently with transplantation. In one aspect, the expanded cells are administered before or after the procedure.

[0531] The dose administered to a patient with a malignant tumor is sufficient to alleviate or at least partially halt the disease being treated (“therapeutic effective dose”). The dose of the above treatment to be administered to a subject will vary depending on the exact nature of the condition being treated and the recipient of treatment. Scaling of the dose for human administration may be performed in accordance with practices generally accepted in the art.

[0532] The CAR T cells of this invention can be expanded from in vivo T cells and can establish prolonged amounts of CD79b-specific memory cells in the blood and bone marrow at high levels. In some cases, the CAR T cells of this invention, infused into a subject, can eliminate cancer cells, such as malignant B cells, in subjects with advanced chemotherapy-resistant cancer.

[0533] In one embodiment, the CAR of this disclosure is introduced into T cells, for example using in vitro transcription, and a subject (e.g., a human) receives an initial administration of the CAR-T cells of this disclosure, followed by one or more subsequent administrations of the CAR-T cells, wherein the one or more subsequent administrations are administered less than 15 days after the previous administration (e.g., 14 days, 13 days, 12 days, 11 days, 10 days, 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, 3 days, or 2 days). In one embodiment, the subject (e.g., a human) is given more than one administration of CAR-T cells per week, for example, two, three, or four administrations of CAR-T cells per week. In one embodiment, the subject receives more than one administration of CAR-T cells per week (e.g., two, three, or four administrations per week) (also referred to herein as a cycle), followed by a week without CAR-T cell administration, and then one or more additional administrations of CAR-T cells (e.g., more than one administration of CAR-T cells per week). In another implementation, the subject receives more than one CAR-T cell cycle, with the time between each cycle being less than 10 days, 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, or 3 days. In one implementation, CAR-T cells are administered every other day, three times a week. In one implementation, CAR-T cells are administered for at least two, three, four, five, six, seven, eight, or more weeks.

[0534] In one implementation, the treatment may be repeated after one, two, three, four, five, six, one week, two weeks, three weeks, one month, five weeks, six weeks, seven weeks, two months, three months, four months, five months, six months, or longer. The treatment course may also be repeated as with chronic administration. Repeated administration may be at the same dose or at different doses.

[0535] CAR-T cells can be administered as a maintenance therapy in the method of the present invention, such as once a week for a period of 6 months or longer.

[0536] In one implementation, lentiviral vectors (such as lentiviruses) are used to generate CAR-T cells. CAR-T cells generated with such viral vectors will typically have stable CAR expression.

[0537] In one implementation, CAR-T cells transiently express the CAR vector for 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, and 15 days after transduction. The transient expression of CAR can be affected by RNA CAR vector delivery. In one implementation, CAR RNA is transduced into T cells via electroporation.

[0538] If a patient is at high risk of developing an anti-CAR antibody response (such as those generated by RNA transduction) during transient CAR therapy, the CAR-T infusion interval should not last more than ten to fourteen days.

[0539] The CAR-expressing cells described herein can be used in combination with other known agents and therapies. As used herein, “combination” administration means the delivery of two (or more) different treatments to a subject during the course of treatment, for example, two or more treatments delivered after the subject has been diagnosed with cancer and before the cancer has been cured or eliminated or treatment has been discontinued for other reasons. In some embodiments, the delivery of one treatment is still in progress when the delivery of the second treatment begins, resulting in an overlap in administration. This is sometimes referred to herein as “simultaneous” or “simultaneous delivery.” In other embodiments, the delivery of one treatment ends before the delivery of the other treatment begins. In some embodiments of either case, the treatment is more effective due to combination administration. For example, the second treatment is more effective than when the second treatment is administered in the absence of the first treatment, or when a similar situation is observed with the first treatment; for example, an equivalent effect is observed with less of the second treatment, or the second treatment alleviates symptoms to a greater extent. In some embodiments, the delivery results in a greater degree of symptom relief or reduction in other disease-related parameters than would be observed when one treatment is delivered in the absence of the other. The effects of the two treatments can be partially additive, completely additive, or greater than the sum of their effects. The delivery method allows the effect of the first treatment to remain detectable when the second treatment is delivered.

[0540] In one implementation, other therapeutic agents (such as factors) may be administered before, after, or simultaneously with CAR-T cells, including but not limited to interleukins and colony-stimulating factors (such as G-CSF, M-CSF, and GM-CSF) and interferons.

[0541] The CAR-expressing cells and at least one additional therapeutic agent described herein may be administered simultaneously, in the same or separate compositions, or sequentially. For sequential administration, the CAR-expressing cells described herein may be administered first, followed by the additional therapeutic agent, or the order of administration may be reversed.

[0542] In another embodiment, the CAR-expressing cells described herein can be used in treatment regimens in combination with surgery, radiation, chemotherapy, immunosuppressants, antibodies, or other immunoablation agents. In yet another embodiment, the CAR-expressing cells described herein can be used in combination with anti-androgen therapy. In one embodiment, an agent that enhances the activity of CAR-expressing cells can be administered to the subject. For example, in one embodiment, the agent can be an agent that inhibits an inhibitory molecule.

[0543] Reagent test kit

[0544] The present invention also provides a kit comprising any of the following: the chimeric antigen receptor (CAR) described herein, and / or a nucleic acid encoding the CAR, a vector containing the nucleic acid, and a host cell containing the vector.

[0545] The kit can be used for therapeutic purposes and as a diagnostic kit.

[0546] The kit can be used to detect the presence of CD79b or CD79b-expressing cells in a sample.

[0547] The kit may contain one or more other components, including: instructions for use; other reagents, such as labels, therapeutic agents, or pharmaceutical agents or radiation protection compositions that can be used to chelate or otherwise conjugate antibodies with labels or therapeutic agents; devices or other materials for preparing the antibody for administration; pharmaceutically acceptable carriers; and devices or other materials for administration to the subject.

[0548] In some implementations, the kit also includes any of the above-mentioned CAR, nucleic acid, vector and / or host cell in a container, as well as instructions for use of the kit.

[0549] In some embodiments, the CAR includes an antigen-binding domain that binds to CD79b, said antigen-binding domain comprising:

[0550] VH of SEQ ID NO:1 and VL of SEQ ID NO:19;

[0551] VH of SEQ ID NO:1 and VL of SEQ ID NO:20;

[0552] VH of SEQ ID NO:2 and VL of SEQ ID NO:19;

[0553] VH of SEQ ID NO:2 and VL of SEQ ID NO:20;

[0554] VH of SEQ ID NO:3 and VL of SEQ ID NO:20;

[0555] VH of SEQ ID NO:4 and VL of SEQ ID NO:19;

[0556] VH of SEQ ID NO:5 and VL of SEQ ID NO:22;

[0557] VH of SEQ ID NO:5 and VL of SEQ ID NO:23;

[0558] VH of SEQ ID NO:6 and VL of SEQ ID NO:24;

[0559] VH of SEQ ID NO:7 and VL of SEQ ID NO:26;

[0560] VH of SEQ ID NO:8 and VL of SEQ ID NO:25;

[0561] VH of SEQ ID NO:9 and VL of SEQ ID NO:27;

[0562] VH of SEQ ID NO:10 and VL of SEQ ID NO:28;

[0563] VH of SEQ ID NO:11 and VL of SEQ ID NO:29;

[0564] VH of SEQ ID NO:12 and VL of SEQ ID NO:30;

[0565] VH of SEQ ID NO:13 and VL of SEQ ID NO:31;

[0566] VH of SEQ ID NO:14 and VL of SEQ ID NO:32;

[0567] VH of SEQ ID NO:15 and VL of SEQ ID NO:33;

[0568] VH in SEQ ID NO:16 and VL in SEQ ID NO:34;

[0569] VH of SEQ ID NO:16 and VL of SEQ ID NO:35;

[0570] VH of SEQ ID NO:17 and VL of SEQ ID NO:33; or

[0571] VH of SEQ ID NO:18 and VL of SEQ ID NO:36.

[0572] In some implementations, the kit contains a CAR with SEQ ID NO: 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, or 118.

[0573] Treatment methods and uses

[0574] This disclosure also provides a method for treating a subject with CD79b-expressing cancer, the method comprising administering to the subject in need a therapeutically effective amount of any of the isolated lymphocytes expressing any of the CARs described herein for a duration sufficient to treat the CD79b-expressing cancer.

[0575] This disclosure also provides a method for treating a subject with CD79b-expressing cancer, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising any of the CARs described herein in isolated lymphocytes for a duration sufficient to treat the CD79b-expressing cancer.

[0576] In one aspect, this disclosure relates entirely to the treatment of subjects at risk of developing cancer. The invention also includes the treatment of malignancies or autoimmune diseases in which chemotherapy and / or immunotherapy result in significant immunosuppression in the subject, thereby increasing the subject's risk of developing cancer.

[0577] This disclosure also provides a method for treating non-cancerous conditions in a subject at risk of developing cancerous conditions, the method comprising administering to the subject any of isolated lymphocytes expressing any of the CARs described herein to treat the non-cancerous conditions.

[0578] This disclosure also provides a method for treating non-cancerous conditions in a subject at risk of developing cancerous conditions, the method comprising administering to the subject a pharmaceutical composition comprising the CAR described herein to treat the non-cancerous conditions.

[0579] This disclosure also provides a method for preventing CD79b-expressing cancers in a subject, the method comprising administering to the subject a therapeutically effective amount of the antigen-binding domain of this disclosure that binds to CD79b for a duration sufficient to prevent CD79b-expressing cancers. Examples of CD79b-expressing cancers include, but are not limited to: B-cell lymphoma, non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZ), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), mucosa-associated lymphoid tissue (MALT) lymphoma, Hodgkin lymphoma, Burkitt lymphoma, hairy cell leukemia, and plasmacytoma.

[0580] This disclosure also provides a method for preventing CD79b-expressing cancers in a subject, the method comprising administering to the subject a therapeutically effective amount of a protein comprising the antigen-binding domain of the present disclosure that binds to CD79b, for a duration sufficient to prevent CD79b-expressing cancers. Examples of CD79b-expressing cancers include, but are not limited to: B-cell lymphoma, non-Hodgkin lymphoma, DLBCL, MCL, FL, MZ, ALL, CLL, MM, MALT lymphoma, Hodgkin lymphoma, Burkitt lymphoma, hairy cell leukemia, and plasmacytoma.

[0581] This disclosure also provides a method for preventing CD79b-expressing cancers in a subject, the method comprising administering to the subject a therapeutically effective amount of a multispecific protein comprising an antigen-binding domain of the present disclosure that binds to CD79b, for a duration sufficient to prevent CD79b-expressing cancers. Examples of CD79b-expressing cancers include, but are not limited to: B-cell lymphoma, non-Hodgkin lymphoma, DLBCL, MCL, FL, MZ, ALL, CLL, MM, MALT lymphoma, Hodgkin lymphoma, Burkitt lymphoma, hairy cell leukemia, and plasmacytoma.

[0582] This disclosure also provides a method for preventing CD79b-expressing cancers in a subject, the method comprising administering to the subject a therapeutically effective amount of any of the CAR-T cells described herein that bind to CD79b, for a duration sufficient to prevent CD79b-expressing cancers. Examples of CD79b-expressing cancers include, but are not limited to: B-cell lymphoma, non-Hodgkin lymphoma, DLBCL, MCL, FL, MZ, ALL, CLL, MM, MALT lymphoma, Hodgkin lymphoma, Burkitt lymphoma, hairy cell leukemia, and plasmacytoma.

[0583] This disclosure also provides a method for preventing CD79b-expressing cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of any of the isolated lymphocytes expressing any of the CARs described herein, for a duration sufficient to prevent CD79b-expressing cancer. Examples of CD79b-expressing cancers include, but are not limited to: B-cell lymphoma, non-Hodgkin lymphoma, DLBCL, MCL, FL, MZ, ALL, CLL, MM, MALT lymphoma, Hodgkin lymphoma, Burkitt lymphoma, hairy cell leukemia, and plasmacytoma.

[0584] In some implementations, cancers expressing CD79b are B-cell lymphomas.

[0585] In some implementations, cancers expressing CD79b are non-Hodgkin lymphomas.

[0586] In some implementations, cancers expressing CD79b have already metastasized.

[0587] In some implementations, cancers expressing CD79b include diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZ), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), mucosa-associated lymphoid tissue (MALT) lymphoma, Hodgkin's lymphoma, Burkitt's lymphoma, hairy cell leukemia, and plasmacytoma.

[0588] In one aspect, this disclosure provides a method for treating a subject with cancer, the method comprising administering any of the isolated lymphocytes expressing any of the CARs described herein, whereby the lymphocytes induce or regulate the killing of cancer cells in the subject.

[0589] Any of the isolated lymphocytes expressing any of the CARs described herein can be used in conjunction with other therapeutic agents or therapies. Such systems can avoid repeated administration of the composition, thereby increasing convenience for subjects and physicians, and can be particularly suitable for certain compositional embodiments of the present invention.

[0590] Administration of any of the isolated lymphocytes expressing any of the CARs described herein can be performed in any manner, such as parenteral or non-parenteral administration, including via aerosol inhalation, injection, infusion, uptake, intravenous infusion, implantation, or transplantation. For example, the CD79 binding protein and compositions described herein can be administered to patients via artery, intradermal, subcutaneous, intratumoral, intramedullary, intranodal, intramuscular, intravenous (iv), or intraperitoneal injection. In one aspect, the compositions of this disclosure are administered via intravenous injection. In another aspect, the compositions of this disclosure are administered to subjects via intradermal or subcutaneous injection. The CD79 binding protein compositions can be injected, for example, directly into tumors, lymph nodes, tissues, organs, or sites of infection.

[0591] In one implementation, the treatment may be repeated after one, two, three, four, five, six, one week, two weeks, three weeks, one month, five weeks, six weeks, seven weeks, two months, three months, four months, five months, six months, or longer. The treatment course may also be repeated as with chronic administration. Repeated administration may be at the same dose or at different doses.

[0592] combination therapy

[0593] Any of the isolated lymphocytes expressing any of the CARs described herein may be administered in combination with at least one additional therapeutic agent.

[0594] In some embodiments, the at least one additional therapeutic agent is surgery, chemotherapy, androgen blocking therapy, or radiation therapy, or any combination thereof.

[0595] In some embodiments, the delivery of one treatment continues while the delivery of the second treatment begins, resulting in an overlap in administration. This is sometimes referred to herein as “simultaneous” or “simultaneous delivery.” In other embodiments, the delivery of one treatment ends before the delivery of the other treatment begins. In some embodiments of either case, the treatments are more effective due to the combined administration. For example, the second treatment is more effective than a similar situation observed when the second treatment is administered in the absence of the first treatment, or when the first treatment is used; for example, an equivalent effect is observed when less of the second treatment is used, or the second treatment alleviates symptoms to a greater extent. In some embodiments, the delivery results in a greater reduction in symptoms or other disease-related parameters than would be observed if one treatment were delivered without the other. The effects of the two treatments can be partially additive, completely additive, or greater than the sum of their parts. The delivery can be such that the effect of the first treatment delivered remains detectable when the second treatment is delivered.

[0596] In one implementation, other therapeutic agents (such as factors) may be administered before, after, or simultaneously with any of the isolated lymphocytes expressing any of the CARs described herein, including but not limited to interleukins and colony-stimulating factors (such as G-CSF, M-CSF, and GM-CSF) and interferons.

[0597] Any isolated lymphocyte expressing any of the CARs described herein may contain at least one additional therapeutic agent, which may be administered simultaneously, in the same or separate compositions, or sequentially. For sequential administration, the lymphocytes described herein may be administered first, and the additional therapeutic agent may be administered second, or the order of administration may be reversed.

[0598] In another embodiment, the lymphocytes described herein may be used in treatment regimens in combination with surgery, radiation, chemotherapy, immunosuppressants, antibodies, or other immunoablation agents. In yet another embodiment, the lymphocytes described herein may be used in combination with anti-androgen therapy. In one embodiment, an agent that enhances the activity of the lymphocytes may be administered to the subject. For example, in one embodiment, the agent may be an agent that inhibits an inhibitory molecule.

[0599] The following examples are provided to further describe some of the embodiments disclosed herein. These examples are intended to illustrate, and not limit, the embodiments disclosed herein.

[0600] An exemplary implementation scheme is described below:

[0601] 1. A chimeric antigen receptor (CAR), said CAR comprising:

[0602] (a) An extracellular domain that specifically binds to the CD79b antigen.

[0603] (b) Transmembrane domains, and

[0604] (c) Intracellular signal transduction domain, wherein the intracellular signal transduction domain optionally includes at least one co-stimulatory domain.

[0605] 2. The CAR according to embodiment 1, wherein the CAR further comprises

[0606] (d) CD8a hinge area,

[0607] The transmembrane domain comprises a CD8a transmembrane region (CD8a-TM) polypeptide; and

[0608] The intracellular signal transduction domains include a co-stimulatory domain and a primary signal transduction domain. The co-stimulatory domain contains a component of TNF receptor superfamily member 9 (CD137), and the primary signal transduction domain contains a component of the T cell surface glycoprotein CD3ζ chain (CD3z).

[0609] 3. The CAR according to implementation scheme 2, wherein

[0610] The CD8a hinge region contains an amino acid sequence that is at least 90% identical to SEQ ID NO:38;

[0611] The transmembrane domain contains an amino acid sequence that is at least 90% identical to SEQ ID NO:39; and / or

[0612] The intracellular signal transduction domain includes a co-stimulatory domain and a primary signal transduction domain. The co-stimulatory domain has an amino acid sequence that is at least 90% identical to that of SEQ ID NO:40, and the primary signal transduction domain has an amino acid sequence that is at least 90% identical to that of SEQ ID NO:41.

[0613] 4. A chimeric antigen receptor (CAR), said CAR comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises:

[0614] The heavy chain complementarity-determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:208, the heavy chain CDR2 having the amino acid sequence of SEQ ID NO:209, and the heavy chain CDR3 having the amino acid sequence of SEQ ID NO:210.

[0615] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:216, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:217, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:218;

[0616] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:222, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:223, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:224;

[0617] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:228, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:217, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:229;

[0618] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:232, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:233, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:234;

[0619] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:238, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:239, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:240;

[0620] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:242, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:243, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:244;

[0621] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:248, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:249, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:250;

[0622] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:253, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:254, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:255;

[0623] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:257, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:258, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:259;

[0624] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:263, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:243, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:264;

[0625] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:268, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:269, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:270; or

[0626] Heavy chain CDR1 having the amino acid sequence of SEQ ID NO:274, heavy chain CDR2 having the amino acid sequence of SEQ ID NO:275, and heavy chain CDR3 having the amino acid sequence of SEQ ID NO:276;

[0627] The extracellular antigen-binding domain thereunder binds to the CD79b antigen.

[0628] 5. The CAR according to embodiment 4, wherein the extracellular antigen-binding domain comprises a heavy chain CDR1 having the amino acid sequence of SEQ ID NO:257, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:258, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:259.

[0629] 6. A chimeric antigen receptor (CAR), said CAR comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein said extracellular antigen-binding domain comprises:

[0630] Light chain CDR1 having the amino acid sequence of SEQ ID NO:211, light chain CDR2 having the amino acid sequence of SEQ ID NO:212, and light chain CDR3 having the amino acid sequence of SEQ ID NO:213;

[0631] Light chain CDR1 having the amino acid sequence of SEQ ID NO:214, light chain CDR2 having the amino acid sequence of SEQ ID NO:212, and light chain CDR3 having the amino acid sequence of SEQ ID NO:213;

[0632] Light chain CDR1 having the amino acid sequence of SEQ ID NO:215, light chain CDR2 having the amino acid sequence of SEQ ID NO:212, and light chain CDR3 having the amino acid sequence of SEQ ID NO:213;

[0633] Light chain CDR1 having the amino acid sequence of SEQ ID NO:219, light chain CDR2 having the amino acid sequence of SEQ ID NO:220, and light chain CDR3 having the amino acid sequence of SEQ ID NO:221;

[0634] Light chain CDR1 having the amino acid sequence of SEQ ID NO:225, light chain CDR2 having the amino acid sequence of SEQ ID NO:226, and light chain CDR3 having the amino acid sequence of SEQ ID NO:227;

[0635] Light chain CDR1 having the amino acid sequence of SEQ ID NO:230, light chain CDR2 having the amino acid sequence of SEQ ID NO:231, and light chain CDR3 having the amino acid sequence of SEQ ID NO:221;

[0636] Light chain CDR1 having the amino acid sequence of SEQ ID NO:235, light chain CDR2 having the amino acid sequence of SEQ ID NO:236, and light chain CDR3 having the amino acid sequence of SEQ ID NO:237;

[0637] Light chain CDR1 having the amino acid sequence of SEQ ID NO:241, light chain CDR2 having the amino acid sequence of SEQ ID NO:226, and light chain CDR3 having the amino acid sequence of SEQ ID NO:227;

[0638] Light chain CDR1 having the amino acid sequence of SEQ ID NO:245, light chain CDR2 having the amino acid sequence of SEQ ID NO:246, and light chain CDR3 having the amino acid sequence of SEQ ID NO:247;

[0639] Light chain CDR1 having the amino acid sequence of SEQ ID NO:251, light chain CDR2 having the amino acid sequence of SEQ ID NO:236, and light chain CDR3 having the amino acid sequence of SEQ ID NO:252;

[0640] Light chain CDR1 having the amino acid sequence of SEQ ID NO:251, light chain CDR2 having the amino acid sequence of SEQ ID NO:236, and light chain CDR3 having the amino acid sequence of SEQ ID NO:256;

[0641] Light chain CDR1 having the amino acid sequence of SEQ ID NO:260, light chain CDR2 having the amino acid sequence of SEQ ID NO:261, and light chain CDR3 having the amino acid sequence of SEQ ID NO:262;

[0642] Light chain CDR1 having the amino acid sequence of SEQ ID NO:265, light chain CDR2 having the amino acid sequence of SEQ ID NO:266, and light chain CDR3 having the amino acid sequence of SEQ ID NO:267;

[0643] Light chain CDR1 having the amino acid sequence of SEQ ID NO:271, light chain CDR2 having the amino acid sequence of SEQ ID NO:272, and light chain CDR3 having the amino acid sequence of SEQ ID NO:273; or

[0644] Light chain CDR1 having the amino acid sequence of SEQ ID NO:277, light chain CDR2 having the amino acid sequence of SEQ ID NO:266, and light chain CDR3 having the amino acid sequence of SEQ ID NO:278;

[0645] The extracellular antigen-binding domain thereunder binds to the CD79b antigen.

[0646] 7. The CAR according to embodiment 6, wherein the extracellular antigen-binding domain comprises a light chain CDR1 having the amino acid sequence of SEQ ID NO:260, a light chain CDR2 having the amino acid sequence of SEQ ID NO:261, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:262.

[0647] 8. The CAR according to embodiment 4 or embodiment 5, wherein the extracellular antigen-binding domain further comprises:

[0648] Light chain CDR1 having the amino acid sequence of SEQ ID NO:211, light chain CDR2 having the amino acid sequence of SEQ ID NO:212, and light chain CDR3 having the amino acid sequence of SEQ ID NO:213;

[0649] Light chain CDR1 having the amino acid sequence of SEQ ID NO:214, light chain CDR2 having the amino acid sequence of SEQ ID NO:212, and light chain CDR3 having the amino acid sequence of SEQ ID NO:213;

[0650] Light chain CDR1 having the amino acid sequence of SEQ ID NO:215, light chain CDR2 having the amino acid sequence of SEQ ID NO:212, and light chain CDR3 having the amino acid sequence of SEQ ID NO:213;

[0651] Light chain CDR1 having the amino acid sequence o...

Claims

1. A chimeric antigen receptor (CAR), said CAR comprising: (a) An extracellular antigen-binding domain that specifically binds to the CD79b antigen. (b) Transmembrane domains, and (c) Intracellular signal transduction domains, The extracellular antigen-binding domain comprises a heavy chain variable region (VH) and a light chain variable region (VL). The VH and VL contain heavy chain complementarity-determining regions 1 (CDR1), 2 heavy chain CDR2, 3 heavy chain CDR3, 1 light chain CDR1, 2 light chain CDR2, and 3 light chain CDR3, represented by the following amino acid sequences: They are SEQ ID NO: 257, 258, 259, 260, 261 and 262 respectively.

2. The CAR according to claim 1, wherein the extracellular antigen-binding domain comprises: The heavy chain variable region is represented by an amino acid sequence having at least 90% identity with SEQ ID NO: 14, and the light chain variable region is represented by an amino acid sequence having at least 90% identity with SEQ ID NO:

32.

3. The CAR according to claim 1 or 2, wherein the extracellular antigen-binding domain comprises: The heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 14 and the light chain variable region represented by the amino acid sequence of SEQ ID NO:

32.

4. The CAR according to claim 1 or 2, wherein the extracellular antigen-binding domain comprises a single-chain variable fragment (scFv), the scFv comprising a heavy chain variable region (VH) and a light chain variable region (VL).

5. The CAR of claim 4, wherein the scFv comprises a linker polypeptide located between the heavy chain variable region (VH) and the light chain variable region (VL).

6. The CAR according to claim 5, wherein the adapter polypeptide is represented by an amino acid sequence having at least 90% identity with SEQ ID NO:

42.

7. The CAR according to claim 5, wherein the adapter polypeptide is represented by the amino acid sequence of SEQ ID NO:

42.

8. The CAR according to claim 4, wherein the scFv is represented by an amino acid sequence having at least 90% identity with SEQ ID NO:

113.

9. The CAR according to claim 4, wherein the scFv is represented by the amino acid sequence of SEQ ID NO:

113.

10. The CAR according to claim 1 or 2, wherein the extracellular antigen-binding domain comprises a signaling polypeptide.

11. The CAR of claim 10, wherein the signaling polypeptide is represented by an amino acid sequence having at least 90% identity with the sequence SEQ ID NO:

37.

12. The CAR according to claim 10, wherein the signaling polypeptide is represented by the amino acid sequence of SEQ ID NO:

37.

13. The CAR according to claim 1 or 2, wherein the intracellular signal transduction domain comprises a polypeptide component selected from the group consisting of: TNF receptor superfamily member 9 (CD137) component, T cell surface glycoprotein CD3ζ chain (CD3z) component, differentiation cluster (CD27) component, differentiation cluster superfamily member component, and combinations thereof.

14. The CAR according to claim 13, wherein the CD137 component is represented by an amino acid sequence having at least 90% identity with the sequence SEQ ID NO:

40.

15. The CAR according to claim 13, wherein the CD137 component is represented by the amino acid sequence of SEQ ID NO:

40.

16. The CAR of claim 13, wherein the CD3z component is represented by an amino acid sequence having at least 90% identity with the sequence SEQ ID NO:

41.

17. The CAR according to claim 13, wherein the CD3z component is represented by the amino acid sequence of SEQ ID NO:

41.

18. The CAR according to claim 1 or 2, wherein the intracellular signal transduction domain is represented by an amino acid sequence having at least 90% identity with the sequence SEQ ID NO:

163.

19. The CAR according to claim 1 or 2, wherein the intracellular signal transduction domain is represented by the amino acid sequence of SEQ ID NO:

163.

20. The CAR according to claim 1 or 2, wherein the transmembrane domain is a CD8a transmembrane region (CD8a-TM) polypeptide.

21. The CAR of claim 20, wherein the CD8a-TM polypeptide is represented by an amino acid sequence having at least 90% identity with the sequence SEQ ID NO:

39.

22. The CAR of claim 20, wherein the CD8a-TM polypeptide is represented by the amino acid sequence of SEQ ID NO:

39.

23. The CAR according to claim 1 or 2, wherein the CAR further comprises a hinge region connecting the transmembrane domain to the extracellular antigen-binding domain.

24. The CAR according to claim 23, wherein the hinge region is a CD8a hinge region.

25. The CAR of claim 24, wherein the CD8a hinge region is represented by an amino acid sequence having at least 90% identity with SEQ ID NO:

38.

26. The CAR of claim 24, wherein the CD8a hinge region is represented by the amino acid sequence of SEQ ID NO:

38.

27. The CAR according to claim 1 or 2, wherein the extracellular antigen-binding domain is represented by an amino acid sequence having at least 90% identity with SEQ ID NO:

157.

28. The CAR according to claim 1 or 2, wherein the extracellular antigen-binding domain is represented by the amino acid sequence of SEQ ID NO:

157.

29. The CAR according to claim 1 or 2, wherein the CAR is represented by an amino acid sequence having at least 90% identity with SEQ ID NO:

202.

30. The CAR according to claim 1 or 2, wherein the CAR is represented by the amino acid sequence of SEQ ID NO:

202.

31. An isolated lymphocyte expressing CAR according to any one of claims 1-30.

32. The isolated lymphocytes according to claim 31, wherein the lymphocytes are T lymphocytes.

33. The isolated lymphocytes according to claim 31, wherein the lymphocytes are natural killer (NK) cells.

34. An isolated nucleic acid molecule, said isolated nucleic acid molecule encoding a CAR according to any one of claims 1-30.

35. A vector comprising the nucleic acid molecule according to claim 34.

36. A cell that expresses the nucleic acid molecule according to claim 34.

37. A pharmaceutical composition comprising an effective amount of isolated lymphocytes according to any one of claims 31-33 and a pharmaceutically acceptable excipient.

38. Use of the isolated lymphocytes according to any one of claims 31-33 in the preparation of a medicament for treating B-cell lymphoma in a subject, wherein the B-cell lymphoma is selected from diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL).

39. The use according to claim 38, wherein the B-cell lymphoma is DLBCL.

40. The use according to claim 38, wherein the B-cell lymphoma is MCL.

Citation Information

Patent Citations

  • Recombinant antibodies and methods for their production

    EP0239400B1

  • Chimeric antibodies

    GB2188638A

  • Immunotherapy using interleukin 13 receptor subunit alpha 2

    US20020197266A1

  • Covalent diabodies and uses thereof

    US20070004909A1

  • Engineered heterodimeric protein domains

    US20070287170A1